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ABSTRACT
Cell membrane is a barrier to be overcome for efficient delivery of therapeutics
into a target site in cytoplasm or nucleus. The hydrophobic phospholipids are major
components of the cell membrane that obstruct the transportation of therapeutics.
Thus, various delivery systems, such as liposomes, nanoparticles and viral vectors,
have been developed to transfer small molecules, peptides, proteins, and
oligonucleotides across the membrane.
Negatively charged phosphopeptides, oligonucleotides, and siRNAs have
emerged as potential therapeutic agents. Phosphopeptides mimic phosphoproteins,
which give on/off signal to many enzymes through interactions with protein kinases.
For example, phosphopeptide pTyr-Glu-Glu-Ile (pYEEI) is an optimal peptide ligand
for binding to the Src tyrosine kinase SH2 domain. Oligonucleotides have been
introduced as antisense drugs to inhibit the translation of mRNA that transfers the
coding information from genes. Small interfering RNA (siRNA)-based therapy has
been also spotlighted since the discovery of RNA interference (RNAi) phenomenon.
However, the cellular delivery of phosphopeptides, oligonucleotides, and siRNAs is a
major obstacle despite many advantages of these compounds. Phosphopeptides
contain negatively charged phosphate group, and/or negatively charged amino acids,
such as glutamic acid or aspartic acid, in their sequences. Oligonucleotides and
siRNAs are polymers composed of nucleosides, which are connected through
negatively charged phosphodiester groups. These negatively charged molecules are
hard to enter cancer cells by diffusion because cancer cell membranes are composed of
negatively charged lipids. In addition, when a naked siRNA is administered in vivo, it

does not show efficient cellular uptake in most mammalian cells and is quickly
disappeared in the blood. Thus, developing carriers to improve the cellular uptake
delivery of negatively charged cell-impermeable compounds has become a subject of
major interest. Novel strategies are urgently needed to circumvent the problems
associated with the delivery of these compounds.
Cell-penetrating peptides (CPPs) have become one of the emerging vehicles for
delivery of cargo drugs. CPPs are short hydrophilic or amphiphilic peptides that have
plenty of positively charged amino acids, such as lysine or arginine, which can
penetrate cell membranes. CPP-drug conjugates have been reported to help the cellular
uptake of some drugs. Alternatively, they have been used as non-covalent drug
delivery systems.
CPPs have been investigated for improving the intracellular delivery of
negatively-charged molecules. By physical interaction between positive charges in
CPPs and negative charges in phosphopeptides, oligonucleotides, and siRNAs, the cell
penetration could be improved. Among many CPPs, arginine-rich peptides have been
the subject of major focus because it has been known that the guanidine group of
arginine side chain shows better interaction with the negatively charged phospholipid
in the cell membrane. Tryptophan is also a key amino acid found in CPPs that
enhances the interaction of peptides with lipids in the cell membrane.
Parang’s laboratory has previously shown that monocyclic CPPs containing
alternative arginine and tryptophan have potential applications for drug delivery.
Cyclic peptides have several benefits compared to linear peptides, such as stability
against proteolytic enzymes and rigidness of structure. The rigidity of the structure can

enhance the binding affinity of ligands toward receptors by reducing the freedom of
possible structural conformations. Cyclic peptides are also present in nature and have
been developed as therapeutics. Cyclosporin, gramicin S, polymoxin B, and
daptomycin are well-known examples of cyclic peptides. Parang’s laboratory designed
amphiphilic cyclic CPPs containing alternative tryptophan and arginine residues as the
hydrophobic and positively charged residues, respectively. The peptides were efficient
in improving the cellular delivery of anticancer and antiviral drugs.
In this dissertation, we designed novel classes of amphiphilic cyclic peptides for
improving the intracellular delivery of cell-impermeable phosphopeptides, and their
antimicrobial activities were investigated. The hypothesis of this dissertation is that
amphiphilic cyclic peptides, having positively charged arginines on one side of
structures and hydrophobic tryptophan (or fatty acid) on the other side, can enhance
intracellular drug delivery and/or act as antimicrobial agents having synergy with
other antibiotics.
In Manuscript I (Submitted to Angewandte Chemie International Edition), we
designed amphiphilic bicyclic peptides as cellular delivery agents. The objective of
this manuscript was to design a novel class of bicyclic CPPs containing two
monocyclic peptides of tryptophan and arginine amino acids. Two bicyclic peptides
[W5G]-(triazole)-[KR5] and [W5E]-(-Ala)-[KR5] were synthesized by conjugation of
two monocyclic peptides using click chemistry and amide synthesis, respectively. A
corresponding linear peptide, W5G-(triazole)-KR5, and a monocyclic peptide with a
linear component, [W5G]-(triazole)-KR5, were synthesized as controls. Among all
peptides, [W5E]-(-Ala)-[KR5] improved the cellular delivery of fluorescein-labeled

phosphopeptide, F-GpYEEI by 19.3-fold. Confocal microscopy showed that the
corresponding fluorescein-labeled bicyclic peptide F-[KW4E]-(-Ala)-[KR5] was
localized in the cytosol and nucleus in human ovarian adenocarcinoma (SK-OV-3)
cells. Studying the cellular uptake of F-[KW4E]-(-Ala)-[KR5] in the presence of
endoycytosis inhibitors indicated that the clathrin- and caveolin-dependent
endocytosis were the main pathways for cellular uptake. [W5E]-(-Ala)-[KR5]
enhanced the intracellular uptake of fluorescein-labeled phosphopeptide, F-GpYEEI
by 4.5- and 3.0-fold compared to those of well-known cell-penetrating peptides
(CPPs), TAT and CR7, respectively. The bicyclic peptide was able to improve
antiproliferative activity of doxorubicin by 20%. Thus, this manuscript suggests that
amphiphilic bicyclic peptides containing tryptophan and arginine can be utilized as a
new class of cell-penetrating peptides and potential cellular delivery tools.
In Manuscript II (Submitted to Molecular Pharmaceutics), we investigated the
role of fatty acylation and cyclization for intracellular transport of phophopepides in
short-length polyarginine peptides Most of the reported arginine-rich CPPs to enhance
intracellular drug delivery are linear peptides, and have more than seven arginines to
retain cell penetrating properties. Herein, we synthesized penta and hexaarginine
peptides (R5 and R6), and explored the effect of acylation and cyclization on the cell
penetrating properties of the peptides. The fluorescence-labeled acylated cyclic
peptide dodecanoyl-[R5] and linear peptide dodecanoyl-(R5) showed approximately
13.7- and 10.2-fold higher cellular uptake than that of control 5(6)-carboxyfluorescein,
respectively. The mechanism of the peptide internalization into cells was found to be
energy-dependent endocytosis. The molecular transporter property of fatty acylated

cyclic peptides was compared with those of fatty acylated linear peptide and
nonacylated cyclic peptide using flow cytometry. The combination of acylation and
cyclization (dodecanoyl-[R5]) enhanced intracellular delivery of a fluorescencelabeled phosphopeptide (F′-GpYEEI) in human SK-OV-3 cancer cell line.
Dodecanoyl-[R5] and dodecanoyl-[R6] enhanced the intracellular uptake of a
fluorescence-labeled cell impermeable negatively charged phosphopeptide (F′GpYEEI) in human ovarian cancer cells (SK-OV-3) by 3.4-fold and 5.5-fold,
respectively. The cellular uptake of F′-GpYEEI in the presence of hexadecanoyl-[R5]
was 9.3- and 6.0-fold higher than that of in the presence of octanoyl-[R5] and
dodecanoyl-[R5], respectively. A comparative FACS results showed that dodecanoyl[R5] enhanced the cellular uptake of the phosphopeptide by 1.4-2.5 fold higher than
the corresponding linear peptide dodecanoyl-(R5) and those of representative CPPs,
such as hepta-arginine (CR7) and TAT peptide. In this manuscript, we found that a
combination of acylation by long chain fatty acids and cyclization on short argininecontaining peptides can improve their cell-penetrating property, possibly through
efficient interaction of rigid positively charged R and hydrophobic dodecanoyl moiety
with the corresponding residues in the cell membrane phospholipids.
In Manuscript III (to be submitted to Molecular Pharmaceutics), the
antimicrobial activities of cyclic CPPs were investigated against multidrug resistant
pathogens. Antimicrobial peptides and CPPs share similar structural features. Based
on the intracellular delivery property of amphiphilic cyclic peptides in manuscript II,
we synthesized several amphiphilic cyclic CPPs and their analogs, and investigated
antibacterial activities against multidrug resistant pathogens. [R4W4] exhibited a

potent antibacterial activity, exhibiting MIC value of 2.67 µg/mL against methicillinresistant Staphylococcus aureus (MRSA). Cyclic [R4W4] and the linear counterpart
R4W4 exhibited MIC values of 42.8 and 21.7 µg/mL, respectively, against
Pseudomonas aeruginosa. [R4W4] in combination with tetracycline enhanced the
potency, by decreasing the MIC 4 fold (0.12 µg/mL), suggesting partial synergistic
effect of the combination between [R4W4] and tetracycline against MRSA. Twentyfour hour time-kill studies evaluating [R4W4] in combination with tetracycline
demonstrated bactericidal activity against MRSA and E. coli. [R4W4] showed cellpenetrating properties as expected, and exhibited more than 84% cell viability at 15
µM (20.5 µg/mL) concentration against three different human cell lines. This study
suggests that amphiphilic cyclic CPPs, when used in combination with antimicrobials
could provide additional benefit to defeat multi-drug resistant pathogens.
In summary, the studies in this dissertation provided insights and a deep
understanding of applications of cyclic cell-penetrating peptides to enhance
intracellular uptake of cargo drugs, and their antimicrobial activities as drug alone or
combination with other antibiotics. Amphiphilic bicyclic peptides are the first reported
bicyclic peptides as CPPs and molecular transporters. Acylated cyclic polyarginines
showed that short polyarginines can be utilized as CPPs to have cell-penetrating
properties by combining fatty acylation and cyclization. Moreover, this study provided
a potential of amphiphilic cyclic CPPs as antimicrobial agents that their potency could
be maximized by the combination with other antibiotics possibly through their drug
delivery properties. Overall, these findings will be beneficial for the scientific

community in academia and industry working in the area of designing molecular
transporters of cell impermeable compounds, and cellular delivery.
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Abstract
Two

bicyclic

peptides

[W5G]-(triazole)-[KR5]

and

[W5E]-(-Ala)-[KR5]

composed of tryptophan and arginine residues were synthesized from monocyclic
peptide building blocks and evaluated as cellular delivery agents. [W5G]-(triazole)[KR5] and [W5E]-(-Ala)-[KR5] containing triazole and β-alanine linkers improved
the cellular delivery of fluorescein-labeled phosphopeptide, F-GpYEEI by 7.6 and
19.3-fold, respectively, in human ovarian adenocarcinoma (SK-OV-3) cells. Confocal
microscopy showed that the corresponding fluorescein-labeled bicyclic peptide F[KW4E]-(-Ala)-[KR5] was localized in the cytosol and nucleus. Studying the cellular
uptake of F-[KW4E]-(-Ala)-[KR5] in the presence of endocytosis inhibitors indicated
that the clathrin- and caveolin-dependent endocytosis were the main pathways for
cellular uptake. The bicyclic peptide was able to improve antiproliferative activity of
doxorubicin by 20%. These data suggest that amphiphilic bicyclic peptides containing
tryptophan and arginine can be utilized as a new class of cell-penetrating peptides and
potential cellular delivery tools.

3

Cell-penetrating peptides (CPPs) have been studied as molecular transporters
because of their cellular translocation properties.[1] Covalent or non-covalent CPPdrug conjugates have been designed to deliver cell-impermeable drugs, such as
negatively charged phosphopeptides, oligonucleotides, and siRNAs.[2] Various CPPs,
such as TAT peptide, antennapedia, or polyarginines, have been used as molecular
transporters for a wide range of molecular cargos.[3,4]
Among CPPs, cyclic peptides take advantage of their higher serum stability
compared to the linear counterparts.[5] In addition, the presence of positively charged
arginine and hydrophobic tryptophan amino acids were found to be critical due to their
characteristic interactions with phospholipid membranes.

[6–8]

We have previously

reported the development of homochiral cyclic peptides containing arginine and
tryptophan [WR]4 and [WR]5 as nuclear-targeting CPPs.[9] These monocyclic peptides
were found to be effective tools as covalent and non-covalent molecular
transporters.[10,11] Our findings showed that in addition to the cyclic nature, the
sequence of the peptide contributes significantly to the molecular transporter property
of the peptide by keeping a balance between both hydrophobic and positively charged
properties.
To the best of our knowledge, bicyclic peptides have not been explored as CPPs
and molecular transporters. We hypothesized that an amphiphilic bicyclic peptide
containing two hydrophobic and positively charged cyclic peptides could act an
alternative cellular delivery tool. Amphiphilic bicyclic peptides containing tryptophan
and arginine amino acids and appropriate controls were synthesized and evaluated as

4

CPPs and molecular transporters of a cell-impermeable negatively charged
phosphopeptide.
Two bicyclic peptides containing triazole and β-alanine linkers were synthesized
to determine the effect of spacers in cellular delivery. First, a monocyclic peptide
containing five arginine residues and one lysine azide [K(N3)R5] and a cyclic peptide
[W5G(propargyl)]

containing

five

tryptophans

and

one

propargylglycine

(G(propargyl)) were prepared and conjugated by click chemistry to generate [W5G](triazole)-[KR5] containing a triazole linker (Figure 1a). Alternatively, bicyclic peptide
[W5E]-(-Ala)-[KR5] was synthesized through linking two monocyclic peptides,
[W5E] and (-Ala)-[KR5], through a -alanine (-Ala) spacer (Figure 1a) (See
Supporting Information for experimental details).
Furthermore, a corresponding linear peptide containing tryptophan and arginine
residues, W5G-(triazole)-KR5, and a monocyclic peptide with a linear component,
[W5G]-(triazole)-KR5, were synthesized as controls (Figure 1a) to determine the effect
of the cyclic nature of the peptide.
First, we examined the cytotoxicity of these peptides by MTS proliferation assay
against human ovarian adenocarcinoma SK-OV-3 cell lines and human embryonic
kidney HEK 293T cell lines. In both cancer and normal cell lines, all four peptides
showed more than 80% cell viability at 10 M concentration (Supporting Information).
Further cytotoxicity of [W5E]-(-Ala)-[KR5] was determined against a non-adherent
cell line (human leukemia CCRF-CEM) after 24 h. The data showed that cell viability
at 15 M peptide concentration was remained up to 88% in non-adherent CCRF-CEM

5

cell line. Thus, a noncytotoxic concentration of 5-10 M was selected for further
cellular uptake studies.
To determine the ability of these amphiphilic peptides as molecular transporters,
we used a negatively charged fluorescein-labeled phosphopeptide, F-GpYEEI (F =
fluorescein), as a model cell-impermeable compound, which is known as a substrate of
Src kinase SH2 domain.[12,13] F-GpYEEI (5 M) was incubated in SK-OV-3 cells in
the presence of these four peptides (10 M) for 1 h, and the cellular uptake was
evaluated by flow cytometry. All four peptides enhanced the intracellular uptake of FGpYEEI. The cellular uptake of the phosphopeptide was increased 2.9-, 7.2-, 7.6-, and
19.3-fold for linear W5G-(triazole)-KR5, monocyclic [W5G]-(triazole)-KR5, bicyclic
[W5G]-(triazole)-[KR5], and bicyclic [W5E]-(-Ala)-[KR5], respectively. Thus,
[W5E]-(-Ala)-[KR5]

showed

significantly

higher

cellular

delivery

of

the

phosphopeptide among all peptides (Figure 1b). These data showed that amphiphilic
peptides containing tryptophan and arginine residues can enhance the transportation of
a cell impermeable phosphopeptide. Moreover, cyclic nature of the peptide contributes
significantly to the intracellular uptake since all the peptides containing one or two
cyclic peptides showed higher molecular transporter property. In addition, the bicyclic
peptide containing β-alanine linker, [W5E]-(-Ala)-[KR5], exhibited 2.5-fold higher
uptake of the cell-impermeable phosphopeptide than that of bicyclic peptide [W5G](triazole)-[KR5]. [W5E]-(-Ala)-[KR5] has a more flexible linker between two cyclic
peptides. Thus, the nature and the length of the linker between two cyclic peptides are
critical in generating an appropriate conformation for interaction with the cell
membrane phospholipid and molecular transporter property of the compound. Thus,
6

bicyclic peptide [W5E]-(-Ala)-[KR5] was selected for further study and evaluation as
a CPP.
A corresponding fluorescein-labeled bicyclic peptide of [W5E]-(-Ala)-[KR5], F[KW4E]-(-Ala)-[KR5] (F = fluorescein) (Figure 2), was synthesized (See Supporting
Information for experimental details) for cell permeability studies. SK-OV-3 cells
were incubated with the fluorescein-labeled bicyclic peptide (10 M) for 1 h at 37 ⁰C.
Confocal laser scanning microscope (CLSM) images showed that the fluoresceinlabeled bicyclic peptide was dispersed into the nucleus and cytosol (upper panel in
Figure 2a), but no significant fluorescence was observed in the cells treated with
fluorescein (FAM) alone under the same condition (lower panel in Figure 2a). The
diffusion of fluorescence was observed in both cytoplasm and nucleus even though the
punctate fluorescence was detected in FITC image. These data indicate that the
bicyclic peptide is localized in cellular organelles possibly via endocytosis, and the
peptide escapes from endosomes into the cytosol and nucleus.
Flow cytometry analysis was further confirmed the cellular uptake of F-[KW4E](-Ala)-[KR5]. SK-OV-3 cells were incubated for 1 h with the fluorescence-labeled
peptides. The bicyclic peptide showed 2.9-fold more uptake when compared with
fluorescein (FAM) (Figure 2b). The cellular uptake of the bicyclic peptide, F[KW4E]-(-Ala)-[KR5] was found to be 1.8-fold more in comparison to our previously
reported monocyclic F-[W5R4K] peptide[9] at 5 M concentration. These data indicate
that the bicyclic peptide has higher cellular uptake when compared to the
corresponding monocyclic peptide. Thus, this new bicyclic peptide could be used as
an alternative CPP with more efficiency compared to the monocyclic peptide.
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To examine the cellular uptake mechanism of F-[KW4E]-(-Ala)-[KR5], a
temperature control assay was carried out at 4 °C to inhibit the energy-dependent
endocytosis. The uptake of the bicyclic peptide was significantly reduced at 4 °C,
indicating that the cellular uptake mechanism was dependent on the endocytosis
(Figure 3a).[14] To further confirm the energy-dependent cellular uptake of the bicyclic
peptide, SK-OV-3 cells were incubated with sodium azide (10 mM) and 2-deoxy-Dglucose (50 mM) for 1 h before and 1 h after adding the bicyclic peptide to induce
ATP depletion. The result showed that there was inhibition by ATP depletion (Figure
3a), which is consistent with the result of the temperature control assay at 4 °C,
suggesting that endocytosis is the major pathway for the cellular uptake of the bicyclic
peptide as shown for other systems.[15]
The cellular uptake studies were also conducted in the presence of several
endocytosis inhibitors, such as chloroquine, chlorpromazine, methyl -cyclodextrin,
nystatin, and 5-(N-ethyl-N-isopropyl)amiloride (EIPA), to determine the specific
endocytosis mechanism. SK-OV-3 cells were incubated with each inhibitor for 30 min
before 1 h incubation with F-[KW4E]-(-Ala)-[KR5]. The results showed that only
chlorpromazine and nystatin significantly reduced the cellular uptake of the bicyclic
peptide (Figure 3b). Since chlorpromazine is a clathrin-dependent endocytosis
inhibitor and nystatin blocks the lipid raft-caveolae endocytosis,[16,17] we suggest that
the cellular uptake mechanism of F-[KW4E]-(-Ala)-[KR5] is a clathrin- and
caveolin-dependent endocytosis. These data indicate that the cellular uptake of the
bicyclic peptide as a CPP follows a different pattern from that of cyclic peptide [WR]5,
which showed endocytosis-independent cellular uptake.[9]
8

Bicyclic [W5E]-(-Ala)-[KR5] improved the uptake of F-GpYEEI by 19.3-fold as
shown in Figure 1b. To evaluate the molecular transporter property of the bicyclic
peptide compared to a number of other CPPs, such as linear polyarginine (CR 7), TAT,
and monocyclic peptide [WR]5, we carried out the cellular uptake assay using a
fluorescein-labeled phosphopeptide, F-GpYEEI. Negatively charged F-GpYEEI was
used as a model cell impermeable cargo. It was expected that the interaction between
negatively charged phosphopeptides and positively charged bicyclic peptide could
improve the cellular uptake of the phosphopeptide. For cellular uptake assay, we used
a non-cytotoxic concentration of the bicyclic peptide (10 M). For comparative
studies, F-GpYEEI was co-incubated using typical CPPs, such as linear polyarginine
(CR7) and TAT peptides, and monocyclic [WR]5. After incubation of F-GpYEEI with
or without the peptides in SK-OV-3 cells, FACS analysis was carried out to quantify
the F-GpYEEI enhanced by CPPs. The intracellular uptake of F′-GpYEEI in the
presence of the bicyclic peptide was enhanced by 4.5- and 3.0-fold higher than those
of TAT and CR7 peptide, and 1.8-fold over [WR]5 cyclic CPP (See Supporting
Information). Thus, [W5E]-(-Ala)-[KR5] was found to be a more efficient molecular
transporter for the negatively-charged phosphopeptide compared to commonly used
CPPs and our previous reported cyclic CPP.[9] We have previously reported the
binding

affinity

between

monocyclic

[WR]5

and

the

negatively

charged

phosphopeptide. Improved uptake in the presence of the bicyclic peptide could be due
to the higher binding affinity with the phosphopeptide because of the presence of all
positively-charged amino acids at one side and/or higher efficiency of the bicyclic
peptide as a molecular transporter.
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Next, an intracellular retention of a commercially available anticancer drug,
doxorubicin (DOX), was determined in the presence and absence of the bicyclic
peptide. SK-OV-3 cells were incubated with doxorubicin (5 M) and [W5E]-(-Ala)[KR5] (10 M) containing medium for 1 h. Then all compounds and media were
removed, and fresh complete media was added and kept for 24 h. We found that the
bicyclic peptide did not increase the cellular uptake of DOX compared to the free
DOX after 1 h incubation. However, 1.7-fold higher retention of DOX was observed
intracellularly in the presence of the bicyclic peptide after 24 h (Figure 4a).
To determine whether [W5E]-(-Ala)-[KR5] can be exploited for the delivery of
biologically relevant doses of DOX to cells, the antiproliferative activity of DOX was
evaluated in SK-OV-3 cells in the presence and absence of the bicyclic peptide. The
antiproliferative activity of DOX (1 M) in the presence of the [W5E]-(-Ala)-[KR5]
(10 M) was improved by approximately 20% compared to that of DOX alone after 72
h incubation (Figure 4b). An inhibitory effect on the cell proliferation of SK-OV-3
cells suggests improved efficacy of DOX. [W5E]-(-Ala)-[KR5] alone did not show
any toxicity in SK-OV-3 cells under similar conditions, suggesting that the higher
antiproliferative is possibly related to the efflux inhibition of the drug in the presence
of the bicyclic peptide or the time-delayed release of DOX from the endosome after
cellular uptake.
In conclusion, we report synthesized bicyclic peptides, [W5G]-(triazole)-[KR5]
and [W5E]-(-Ala)-[KR5], as a new class of CPPs. To the best of our knowledge, this
is the first bicyclic peptides as a cellular delivery tool. [W5E]-(-Ala)-[KR5] was
internalized through a clathrin-mediated and lipid raft-caveolin-dependent endocytic
10

mechanism, and worked as a molecular transporter for delivery of a negativelycharged phosphopeptide. [W5E]-(-Ala)-[KR5] also enhanced the retention of DOX in
SK-OV-3 cells. Thus, an amphiphilic bicyclic peptide containing two monocyclic
peptides can be used as a CPP and potential cellular delivery vehicle.

Keywords: amphiphiles • bicyclic peptide • cell-penetrating • drug delivery •
endocytosis
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Figures
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Figure 1. (a) The chemical structures of amphiphilic linear, monocyclic, and bicyclic
peptides. (b) Cellular uptake of F’-GpYEEI (F’-PP, 5 M) in SK-OV-3 cells in the
presence of bicyclic peptides (10 M) and their derivatives.
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Figure 2. (a) Confocal Laser Scanning (CLSM) images of SK-OV-3 cells treated with
bicyclic peptide F-[KW4E]-(-Ala)-[KR5] (10 M, upper) and FAM (10 M, lower)
for 1 h; (b) FACS analysis of SK-OV-3 cells incubated with F-[KW4E]-(-Ala)-[KR5]
(5 M) or F-[W5R4K] (5 M) for 1 h.

15

Figure 3. Cellular uptake of F’-[KW4E]-(-Ala)-[KR5] (5 M) in SK-OV-3 cells
incubated (a) at 37 °C and 4 °C, (b) with 10 mM NaN3 and 50 mM 2-deoxy-D-glucose,
and (c) with endocytic inhibitors (CQ: chloroquine; CPZ: chlorpromazine; MCD:
methyl -cyclodextrin; NYS: nystatin; EIPA: 5-(N-ethyl-N-isopropyl) amiloride)
analyzed by flow cytometry.
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Figure 4. (a) The effect of [W5E]-(-Ala)-[KR5] (10 M) on cellular uptake of DOX
(5 M) in SK-OV-3 cells. After 1 h incubation with compounds, the media were
replaced with fresh complete media and kept for 24 h; (b) The antiproliferative assay
of DOX (1 M) in the presence of [W5E]-(-Ala)-[KR5] (10 M) in SK-OV-3 cells for
72 h. After 24 h incubation, the treatment was replaced by fresh media. The cells were
kept in an incubator for 24-72 h.
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Supporting Information
Experimental Section
1. General procedure
Materials. The resins for peptide synthesis, coupling reagents, and Fmoc-protected
amino acid building blocks were purchased from Chem-Impex International, Inc. 2(1H−Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)
was purchased from Oakwood products, Inc. Other chemicals and reagents were
purchased from Sigma-Aldrich Chemical Co.

Solid-phase peptide synthesis. All reactions were carried out manually in a glass
reaction vessel with a sintered glass frit by mixing under nitrogen bubbling at room
temperature, unless otherwise stated. Generally, all linear and monocyclic peptides
were synthesized by the Fmoc/tBu solid phase synthesis strategy, employing N-(9fluorenyl)methoxycarbonyl (Fmoc)-based chemistry and Fmoc-L-amino acid building
blocks, and head-to-tail cyclization method as described previously by us.[9] Single
amino acid loaded 2-chlorotrityl resins were used for conjugation with Fmoc-L-amino
acid building blocks. HBTU and N,N-diisopropylethylamine (DIPEA) in N,Ndimethylformamide (DMF) were used as coupling and activating reagents,
respectively. Fmoc-deprotection at each step was carried out in the presence of
piperidine in DMF (20%) followed by washing with DMF. The linear peptides were
cleaved from the resins and the side chains were deprotected by shaking with freshly
prepared cleavage cocktail of trifluoroacetic acid (TFA)/triisopropylsilane (TIS)/water
(92.5/5/2.5, v/v/v) for 2-3 h. The crude peptides were filtered, and the resins were
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washed again with 2-3 mL of cleavage cocktail. The crude peptides were precipitated
and washed with cold diethyl ether.

For

cyclization,

a

cleavage

cocktail,

2,2,2-trifluoroethanol

(TFE)/acetic

acid/dichloromethane (DCM) (2:1:7, v/v/v) was used for 1 h to cleave side-chain
protected linear peptides from resins. The resins were filtered off, and the filtrate was
repeatedly evaporated and dissolved in a small portion of DCM and hexane. The
obtained side-chain protected linear peptides were kept in vacuum for overnight and
used directly for the cyclization. Cyclization of linear peptides was carried out in the
presence of a mixture of 1-hydroxy-7-azabenzotriazole (HOAT) and N,Ndiisopropylcarbodiimide (DIC) in anhydrous DMF/DCM for 24 h. The solvents were
evaporated and the side-chain deprotection groups of cyclic peptide were removed by
cleavage

cocktails,

TFA/thioanisole/1,2-ethanedithiol

(EDT)/anisole

(90:5:3:2,

v/v/v/v) or TFA/TIS/water (92.5/5/2.5, v/v/v) for 2-3 h reaction. The crude
monocyclic peptides were precipitated and washed with cold diethyl ether.
The crude peptides were purified on a reversed-phase high pressure liquid
chromatography (RP-HPLC) system using Shimadzu LC-8A preparative liquid
chromatography on a Phenomenex Gemini C18 column (10 μm, 250 × 21.2 mm) with
a gradient 0-100% of acetonitrile (CH3CN) containing 0.1% TFA (v/v) and water
containing 0.1% (v/v) for 1 h with a flow rate between 9 to 18 mL/min at 214 nm
wavelength. Purity of some compounds was confirmed by analytical HPLC using an
RP-C18 column (Shimadzu Premier C18, 3 μm, 150 × 4.6 mm). The chemical
structures of final products were confirmed by an AXIMA performance matrix-
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assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometer
(Shimadzu Corporation).

2. Synthesis of linear K(N3)R5. H-Arg(Pbf)-2-chlorotrityl resin (1389 mg, 0.5 mmol,
0.36 mmol/g) was swelled in DMF for 30 min by N2. Fmoc-Arg(Pbf)-OH (1298 mg, 2
mmol, 4 equiv) was coupled to the N-terminal of H-Arg(Pbf)-2-chlorotrityl resin,
using HBTU (758 mg, 2 mmol, 4 equiv) and DIPEA (697 µL, 4 mmol, 8 equiv) in
DMF (7 mL) by agitating the resin for 1 h using N2. After the coupling, the resin was
washed with DMF, followed by Fmoc-deprotection. The subsequent three FmocArg(Pbf)-OH couplings and one Fmoc-Lys(N3)-OH (789 mg, 2 mmol, 4 equiv)
coupling was carried out in the same manner, respectively. The terminal Fmoc group
was deprotected, followed by washing with DMF, DCM, and methanol. The crude Nazido KR5 was cleaved by shaking with a freshly prepared cleavage cocktail,
TFA/TIS/water (92.5:5:2.5, v/v/v, 15 mL) for 3 h, and purified by a method described
in general procedure. K(N3)R5: HPLC (Rt)

= 9.30 min; MALDI-TOF (m/z):

C36H72N24O7 calcd. 952.6016; found 952.9263 [M]+.

3. Synthesis of linear W5G(propargyl). H-Trp(Boc)-2-chlorotrityl resin (769 mg, 0.6
mmol, 0.78 mmol/g) was swelled using DMF, and coupled with Fmoc-Trp(Boc)-OH
(1264 mg, 2.4 mmol, 4 equiv) using HBTU (910 mg, 2.4 mmol, 4 equiv) and DIPEA
(836 µL, 4.8 mmol, 8 equiv) with DMF (10 mL) for 1 h, followed by Fmocdeprotection. The coupling and deprotection cycle was repeated 3 more times
followed by coupling with Fmoc-L-Gly(propargyl)-OH (804 mg, 2.4 mmol, 4 equiv)
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using HBTU (910 mg, 2.4 mmol, 4 equiv), and DIPEA (836 μL, 4.8 mmol, 8 equiv) in
DMF (10 mL). The crude W5G(propargyl) was obtained by TFA/TIS/water cleavage
and precipitation using cold diethyl ether as described above. W5G(propargyl): 1H
NMR (DMSO-d6, 300 MHz,  ppm): 12.63 (s, 1H, COOH), 10.60-10.89 (m, 5H, NH
Trp), 7.94-8.34 (m, 5H, NH), 6.84-7.68 (m, 25H, ArH), 4.42-4.74 (m, 6H, αCH Trp
and Gly(propargyl)), 2.85-3.22 (m, 10H βCH2 Trp), 2.56-2.67 (m, 2H, βCH2
Gly(propargyl)), 1.88 (m, 1H, CH Gly(propargyl)), 1.00 (d, J = 6.5, 2H, NH2); HPLC
(Rt) = 14.00 min; MALDI-TOF (m/z): C60H57N11O7 calcd. 1043.4442; found
1066.6016 [M + Na]+, 1082.1667 [M + K]+.

4. Synthesis of monocyclic peptides. The synthetic procedure is same as the linear
peptide except the cleavage and additional cyclization step as described in the general
procedure. As a representative example, the synthesis of [W5G(propargyl)] is
described here (Scheme S1). The side-chain protected linear W5G(propargyl) was
synthesized as described above. The side chain protected linear peptide was cleaved
from the resin with TFE/acetic acid/DCM mixture and cyclized in the presence of
HOAT (326 mg, 2.4 mmol, 4 equiv) and DIC (371 μL, 2.4 mmol, 4 equiv) in dilute
anhydrous DMF/DCM (5:1, v/v, 250 mL) under N2 with stirring for 24 h.
[W5G(propargyl)]: 1H NMR (DMSO-d6, 300 MHz,  ppm): 10.66-10.84 (m, 5H, NH
Trp), 7.90-8.31 (m, 6H, NH), 6.86-7.55 (m, 25H, ArH), 4.01-4.33 (m, 5H, αCH Trp),
3.70-3.70(s broad, 1H, αCH Gly(propargyl)), 2.98-3.23 (m, 10H βCH2 Trp), 2.54-2.65
(m, 2H, βCH2 Gly(propargyl)), 1.75 (s, 1H, CH Gly(propargyl)); HPLC (Rt) = 28.30
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min; MALDI-TOF (m/z): C60H55N11O6 calcd. 1025.4337; found 1048.1293 [M +
Na]+, 1064.1329 [M + K]+.
[K(N3)R5]: 1H NMR (DMSO-d6, 300 MHz,  ppm): 7.81-8.10 (m, 6H, NH), 6.88-7.24
(s broad, 20H, NH guanidinium), 4.10-4.34 (m, 6H, αCH Arg and Lys), 3.18-3.35(m,
10H, CH Arg), 1.82-1.88 (m, 12H βCH2 Arg and Lys), 1.40-1.60 (m, 16H, CH2 Arg
and ,,CH2 Lys); HPLC (Rt) = 9.20 min; MALDI-TOF (m/z): C36H70N24O6 calcd.
934.5910; found 935.2969 [M + H]+.
[W5E]: HPLC (Rt) = 24.00 min; 1H NMR (DMSO-d6, 300 MHz,  ppm): 12.00 (s, 1H,
COOH), 10.70-10.85 (m, 5H, NH Trp), 7.92-8.25 (m, 6H, NH), 6.90-7.60 (m, 25H,
ArH), 4.18-4.32 (m, 5H, αCH Trp), 3.95-4.05 (m, 1H, αCH Glu), 2.90-3.13 (m, 10H
βCH2 Trp), 2.65-2.77 (m, 4H, β,γ CH2 Glu); MALDI-TOF (m/z): C60H57N11O8 calcd.
1059.4392; found 1082.2554 [M + Na]+, 1098.2372 [M + K]+.
( -Ala)-[KR5]: HPLC (Rt) = 9.28 min; MALDI-TOF (m/z): C39H77N23O7 calcd.
979.6376; found 980.4063 [M + H]+.
The synthetic Schemes for [W5G(propargyl)], [W5E], [K(N3)R5], and (-Ala)-[KR5]
are depicted in Schemes S1-S4, respectively.

5. Conjugation of linear or monocyclic peptides by click chemistry. In general, the
alkyne (1 equiv) and the azide (1 equiv) were dissolved in methanol/water. To this
solution, pentahydrated copper sulphate (1 equiv), copper powder (Cu, 10 equiv),
sodium ascorbate (10 equiv), and DIPEA (2 equiv) were added. The reaction mixture
was stirred at room temperature under N2 and monitored by MALDI-TOF mass
spectra. As a representative example, the synthesis of [W5G]-(click)-[KR5] is
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described here (Scheme S5). [W5G(propargyl)] (7.00 mg, 0.0068 mmol, 1 equiv) and
[K(N3)R5] (6.36 mg, 0.0068 mmol, 1 equiv) were dissolved in CH3OH/H2O (1:1, v/v,
2 mL), and CuSO4.5H2O (1.7 mg, 0.0068 mmol, 1 equiv), Cu (4.32 mg, 0.068 mmol,
10 equiv), sodium ascorbate (13.47 mg, 0.068 mmol, 10 equiv) and DIPEA (2.26 µL,
0.013 mmol, 2 equiv) were added, and the mixture was stirred for 3 h. The mixture
was filtered and the filtrate was dried using rotatory evaporator. The crude peptide
[W5G]-(triazole)-[KR5] was purified using a preparative RP-HPLC and lyophilized to
give 3 mg fluffy brown product. [W5G]-(triazole)-[KR5]: Yield 22% (fluffy brown
solid 3 mg); 1H NMR (DMSO-d6, 300 MHz,  ppm): 10.69-10.92 (m, 5H, NH Trp),
7.98-8.36 (m, 12H, NH), 6.77-7.74 (m, 46H, ArH and NH guanidinium), 4.00-4.40
(m, 6H, αCH Trp and Gly(propargyl)), 3.58-3.95 (broad peak, 6H, αCH Arg and Lys),
2.73-3.29 (m, 24H, βCH Arg and εCH Lys, βCH Trp and Gly(propargyl)), 1.25-1.96
(m, 26H, β,γCH Arg and β,γ,δCH Lys). HPLC (Rt) = 10.60 min; MALDI-TOF (m/z):
C96H125N35O12 calcd. 1960.0247; found 1961.7063 [M + H]+.
[W5G]-(triazole)-KR5: Yield 26% (brown solid, 3.5 mg); HPLC (Rt) = 10.30 min;
MALDI-TOF (m/z): C96H127N35O13 calcd. 1978.0353; found 1979.7148 [M + H]+.
W5G-(triazole)-KR5: Yield 15% (brown solid, 4.0 mg); HPLC (Rt) = 10.30 min;
MALDI-TOF (m/z): C96H129N35O14 calcd. 1996.0458; found 1996.7783 [M]+.

6. Conjugation of monocyclic peptides by peptide bond. The dry powdered
monocyclic peptides, [W5E] (12.7 mg, 0.012 mmol, 1 equiv) and (-Ala)-[R5K]
(11.8mg, 0.012 mmol, 1 equiv), were added to 5 mL glass vial and dissolved in
anhydrous DMF (1 mL) using magnetic bead with stirring at room temperature under
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N2 gas. The coupling and activating reagents, 1-hydroxybenzotriazole (HOBT, 4.21
mg, 0.031 mmol, 2.6 equiv), (Benzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (PyBOP, 8.11 mg, 0.015 mmol, 1.3 equiv), and DIPEA (16.70
μL, 0.096 mmol, 8 equiv) were added. The mixture was stirred for 1 h. After 1 h
reaction, the bicyclic peptide was precipitated using cold diethyl ether and separated
by centrifugation. The crude peptide was purified by RP-HPLC as described above
(Scheme S6). [W5E]-(-Ala)-[KR5]: Yield 15% (white fluffy solid, 3.70 mg); 1H
NMR (DMSO-d6, 300 MHz, δ ppm): 10.70-10.90 (m, 5H, NH Trp), 7.84-8.30 (m,
14H, NH), 6.80-7.84 (m, 45H, ArH and NH, NH2 Arg), 4.14-4.37 (m, 5H, αCH Trp),
3.97-4.16 (m, 7H, αCH Arg and Glu), 3.35-3.57 (m, 4H, βCH β-Ala and εCH Lys),
2.90-3.20 (m, 10H, βCH Trp), 2.20-2.35 (m, 6H, β,γ CH Glu and αCH β-Ala), 2.522.65 (m, 10H, δCH Arg), 1.75-1.93 (m, 12H, βCH Arg and Lys), 1.52-1.72 (m, 14H,
γ,δCH Lys and γCH Arg); HPLC (Rt) = 32.30 min; MALDI-TOF (m/z):
C99H132N34O14 calcd. 2021.0662; found 2022.6672 [M + H]+, 2043.5676 [M + Na]+.

7. Synthesis of fluorescein-labeled monocyclic peptide (F-[KW4E]). H-Trp-(Boc)2-chlorotrityl chloride resin (0.3 mmol, 384 mg, 0.78 mmol/g) was swelled in DMF
for 30 min under N2. Fmoc-Trp(Boc)-OH (632 mg, 1.2 mmol, 4 equiv) was coupled to
N-terminal the resin using HBTU (455 mg, 1.2 mmol, 4 equiv) and DIPEA (418 μL,
2.4 mmol, 8 equiv) in DMF (12 mL) by agitating the resin for 1 h. After completion of
the coupling, the resin was washed with DMF (20 mL × 3) followed by Fmocdeprotection with piperidine in DMF (20% v/v) and again washed with DMF (20 mL
× 3). The subsequent amino acids, Fmoc-Glu(OtBu)-OH (511 mg, 1.2 mmol, 4 equiv),
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Fmoc-Trp(Boc)-OH, Fmoc-Trp(Boc)-OH, (Dde)-Lys(Fmoc)-OH (Dde: N-(1-(4,4dimethyl-2,6-dioxocyclohexylidene)ethyl)) (639 mg, 1.2 mmol, 4 equiv) and Fmoc-βAla-OH (374 mg, 1.2 mmol, 4 equiv) were coupled in a similar manner, followed by
each cycle of deprotection of Fmoc group after each coupling. Then a mixture of 5(6)carboxyfluorescence diisobutyrate (CFDI, 465 mg, 0.9 mmol, 3 equiv), 1-hydroxy-7azabenzotriazole (HOAT, 122 mg, 0.9 mmol, 3 equiv), 7-azabenzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP, 469 mg, 0.9 mmol, 3
equiv), and DIPEA (314 μL, 1.8 mmol, 6 equiv) in anhydrous DMF/DCM (5:1 v/v, 12
mL) was added to the resin-bound linear peptide. The coupling reaction was carried
out for 3 h at room temperature, and the resin was washed with DMF (20 mL × 3).
The Dde protection at N-terminal was deprotected by agitating with hydrazine
monohydrate in DMF (2% v/v, 15 mL × 3, 5 min). The CFDI protection was
deprotected by incubating peptidyl resin with 20% piperdine in DMF (15 mL × 2, 10
min. each) with final washing with DMF (20 mL × 3). Finally, the side chain protected
peptide was cleaved from the resin by shaking the resin with a mixture of TFE/acetic
acid/DCM (2:1:7, v/v/v, 50 mL) for 1 h. The solution was evaporated, and the residue
was dried overnight in a vacuum. The crude peptide was used directly for the
cyclization under a dilute condition with DMF/DCM (5:1, v/v, 250 mL), using HOAT
(163 mg, 1.2 mmol, 4 equiv) and DIC (185 μL, 1.2 mmol, 4 equiv), and stirred for 24
h under nitrogen atmosphere. After cyclization, the solvent was evaporated, and the
side-chain deprotection was carried out by the addition of cleavage cocktail,
TFA/thioanisole/EDT/anisole (90:5:3:2, v/v/v/v, 15 mL) for 2 h. The crude bicyclic
peptide was precipitated and purified as describe above. The synthetic method of F-
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[KW4E] is presented in Scheme S7. F-[KW4E]: 1H NMR (DMSO-d6, 300 MHz, δ
ppm): 11.58 (s, 1H, COOH), 10.62-10.92 (m, 4H, NH Trp) 7.80-8.26 (m, 8H, NH),
6.44-7.66 (m, 29H, ArH), 5.75 (s, 2H, OH), 4.10-4.45 (m, 4H, αCH Trp), 4.92-4.06
(m, 2H, αCH Glu and Lys), 2.58-3.19 (m, 8H, βCH Trp), 1.45-2.30 (m, 16H, α,βCH βAla, β,γCH Glu, and β,γ,δ,εCH Lys; HPLC (Rt) = 18.20 min; MALDI-TOF (m/z):
C79H74N12O15, calcd. 1430.5397; found 1469.4227 [M + K]+.

8. Synthesis of fluorescein-labeled bicyclic peptide (F-[KW4E]-( -Ala)-[KR5]).
The dry powdered fluorescein-labeled cyclic peptide F-[KW4E] (8.9 mg, 0.0062
mmol, 1 equiv), 1-hydroxybenzotriazole (HOBT, 2.16 mg, 0.016 mmol, 2.6 equiv),
and PyBOP (4.19 mg, 0.080 mmol, 1.3 equiv) were dissolved in DMF (1.5 mL).
DIPEA (8.53 μL, 0.049 mmol, 8 equiv) was added dropwise with stirring using
magnetic bead under N2 condition for 10 min. to preactivate COOH group of glutamic
acid followed by dropwise addition of a solution of cyclic peptide (-Ala)-[KR5] (6.00
mg, 0.0062 mmol, 1 equiv) in DMF (0.5 mL) (Scheme S8). The reaction was
monitored by MALDI-TOF, showing completion of the reaction after 40 min. The
crude fluorescein-labeled bicyclic peptide was precipitated by adding cold diethyl
ether. The crude peptide was purified using RP-HPLC method described above. F[KW4E]-( -Ala)-[KR5]:

HPLC

(Rt)

=

10.30

min;

MALDI-TOF

(m/z):

C118H149N35O21, calcd. 2392.1667; found 2393.7971 [M + H]+.

9. Cell culture. Human ovarian carcinoma cell line SK-OV-3, human leukemia cell
line CCRF-CEM, and human embryonic kidney cell line HEK 293T were purchased
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from American Type Culture Collection. The cells were grown in eagle’s minimum
essential medium (EMEM) for SK-OV-3 and HEK 293T, and RPMI-1640 medium
(ATCC, Manassas, VA) for CCRF-CEM, supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin solution (10,000 units of penicillin and 10 mg
of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% CO2 at 37 °C.

10. Confocal laser scanning microscopy (CLSM)
10.1. Cellular uptake of F-[KW4E]-( -Ala)-[KR5] in SK-OV-3. SK-OV-3 cells
were seeded with complete EMEM on coverslips in 6-well plate (1 × 105 cells/well)
and kept until 50% confluency. The media were removed and cells were incubated
with 10 M F-[KW4E]-(-Ala)-[KR5] in Gibco® Opti-MEM® I reduced serum
medium (Life Technologies, Grand Island, NY) for 1 h at 37 ⁰C. Then cells were
washed with 1X phosphate buffered saline with calcium and magnesium (PBS +) three
times. The coverslips were mounted on microscope slides, and images were obtained
using Carl Zeiss LSM 700 system with a 488 nm argon ion laser excitation and a BP
505-530 nm band pass filter.

11. Flow cytometry
11.1. Cellular uptake of fluorescein-labeled bicyclic peptide. SK-OV-3 cells were
grown in 6-well plates (2 × 105 cells/well) with complete EMEM media prior 24 h to
add F-[KW4E]-(-Ala)-[KR5]. The 1 mM of fluorescein-labeled bicyclic peptide stock
solution was prepared in water and diluted in Gibco® Opti-MEM® I reduced serum
medium to generate 5 M concentration. The culture media were removed from 6-well
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plates, and the prepared 5 M fluorescein-labeled bicyclic peptide solution was added.
After 1 h incubation, trypsin-EDTA solution was added to detach cells from plate’s
surface and remove cell surface binding peptides. After 5 min of treatment with
trypsin-EDTA, a portion of complete media was added to stop the activity of trypsin.
The cell lines were collected and centrifuged at 2500 rpm. Then they were washed
twice using PBS without calcium and magnesium, and prepared in FACS buffer for
cell sorting. Finally, the cells were analyzed by BD FACSCalibur™ or FACSVerse™
flow cytometer using FL1/FITC channel. The data collection was based on the mean
fluorescence signal for 10,000 cells. All assays were carried out in triplicate. 5(6)Carboxyfluorescein (FAM) was used as the negative control.

11.2. Mechanistic study of cellular uptake by removing energy sources. To
examine the cellular uptake mechanism F-[KW4E]-(-Ala)-[KR5] at low temperature,
the uptake assay was carried out at 4 °C to inhibit the energy-dependent cellular
uptake. SK-OV-3 cells were preincubated at 4 °C for 15 min, and incubated with the
fluorescein-labeled bicyclic peptide for 1 h at 4 °C. Cells were collected and assessed
with the same protocol described in cellular uptake of fluorescein-labeled bicyclic
peptide. The data collected at 37 °C were used for control. For the ATP-depletion
assay, cells were incubated with 10 mM sodium azide and 50 mM 2-deoxy-D-glucose
for 1 h before adding the fluorescein-labeled bicyclic peptide. During 1 h incubation,
the 50 M of fluorescein-labeled bicyclic peptide was prepared in the Opti-MEM® I
reduced serum medium in the presence of 10 mM sodium azide and 50 mM 2-deoxy-Dglucose. Then the cells were incubated with this solution for 1 h. The protocol for
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sample preparation and flow cytometry analysis was same with the protocol described
in cellular uptake of fluorescein-labeled bicyclic peptide.

11.3. Cellular uptake pathway study using endocytosis inhibitors. The cellular
uptake studies were also conducted in the presence of several endocytosis inhibitors.
Chloroquine (100 M), chlorpromazine (30 M), methyl -cyclodextrin (2.5 mM),
nystatin (50 g/mL), and 5-(N-ethyl-N-isopropyl)amiloride (EIPA, 50 M) were used.
SK-OV-3 cells were incubated with each inhibitor for 30 min before 1 h incubation
with F-[KW4E]-(-Ala)-[KR5]. The protocol for sample preparation and flow
cytometry analysis was same with the protocol described in cellular uptake of
fluorescein-labeled bicyclic peptide.

12. Cytotoxicity assay by MTS assay. MTS proliferation assays were performed
against two human cancer cell lines (SK-OV-3 and CCRF-CEM) and one human
normal cell line (HEK 293T). Cells were seeded on 96-well plates (5 × 103 cells for
SK-OV-3, 1 × 105 cells for CCRF-CEM, and 1 × 104 cells for HEK 293T) and
incubated with 100 L of complete media for overnight. The various concentrations
(0– 600 M) of the bicyclic peptide solution (10 L) were added to cells, and kept at
37 C with 5% CO2 for 24 h. Then 20 L of CellTiter 96 aqueous solution were added
on each well and incubated at 37 C with 5% CO2 for 1-4 h. The absorbance was
obtained at 490 nm using microplate reader. The cells without any peptide were used
as control.
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We carried out cytotoxic assay of all peptides against two adherent cell lines (SK-OV3 and HEK 293T) using above protocol (Figure S1). In case of [W5E]-(-Ala)-[KR5],
we examined further cytotoxicity against non-adherent cell line (human leukemia
CCRF-CEM). The result of cytoxicity against CCRF-CEM was presented at Figure
S2.

13. Cellular uptake of a phosphopeptide, F-GpYEEI in the presence of peptides.
To evaluate and compare the molecular transporter property of the bicyclic peptides,
their analogues, and other representative CPPs ([WR]5, TAT, CR7), the following
procedure was employed. SK-OV-3 cells were seeded in 6-well plates (2 × 105
cells/well) and grown with complete EMEM media for overnight. A fluoresceinlabeled phosphopeptide, F-GpYEEI (5 M), and synthesized peptides (10 M) were
premixed in OPTI-MEM I® reduced serum medium at room temperature for 30 min.
Then the cells were incubated with the premixed solution at 37 C with 5% CO2 for 1
h. The sample preparation for FACS analysis was carried out with the same protocol
described for cellular uptake for fluorescein-labeled bicyclic peptide. DMSO and FGpYEEI were used as a negative control (Figure S3).

14. Cellular uptake of doxorubicin (DOX). DOX uptake in the presence of the
bicyclic peptide was performed in SK-OV-3 cells. Dox (5 M) and the bicyclic peptide
(10 M) were premixed in OPTI-MEM I® reduced serum medium. The premixed
solution was added to cells and kept for 1 h at 37 C with 5% CO2. Then the media
were replaced by fresh complete media and incubated for 24 h. The sample
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preparation and FACS analysis were the same as described above except using
FL2/PE channel.

15. Antiproliferative assay of doxorubicin in the presence of the bicyclic peptide.
The antiproliferative activity of DOX alone and in the presence of [W5E]-(β-Ala)[KR5] against SK-OV-3 cells was determined by MTS assay. All cells were plated
overnight in 96-well plates with a density of 5000 cells per well in 0.1 mL of
appropriate growth medium at 37 °C. DOX alone (1 µM) or a combination of DOX (1
µ M) and [W5E]-(β-Ala)-[KR5] (10 µ M) were incubated with the cells for 24 h. After 24
h incubation, the treatment was replaced by fresh media. The cells were kept in an
incubator for 24-72 h. The cells without compounds were included in each experiment
as controls. After each incubation period of time, 20 µL of MTS solution was added
and incubated for 2 h. The absorbance of the formazan product was measured at 490
nm using a microplate reader. The percentage of cell viability was calculated as (OD
value of untreated cells − OD value of treated cells)/OD value of untreated cells ×
100%.
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Figures for supporting information

Figure S1. Cytotoxicity of amphiphilic peptides in human ovarian adenocarcinoma
SK-OV-3 and human embryonic kidney HEK 293T cells after 24 h incubation.
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Figure S2. Cytotoxicity of [W5E]-(-Ala)-[KR5] against human leukemia CCRFCEM cell after 24 h incubation.
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Figure S3. Cellular uptake of F-GpYEEI (F-PP, 5 µM) in SK-OV-3 cells in the
presence of cell-penetrating peptides (10 µM). The sequences of CR7 and TAT are
CRRRRRRR-NH2 and YGRKKRRQRRR-NH2, respectively.
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Schemes for supporting information

Scheme S1. The synthesis of monocyclic peptide [W5G(propargyl)].
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Scheme S2. The synthesis of monocyclic peptide [W5E].
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Scheme S3. The synthesis of monocyclic peptide [K(N3)R5].
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Scheme S4. The synthesis of monocyclic peptide (β-Ala)-[KR5].
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Scheme S5. The conjugation of two monocyclic peptides for the synthesis of [W5G](triazole)-[KR5] peptide.
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Scheme S6. The conjugation of two monocyclic peptides for the synthesis of [W5E](β-Ala)-[KR5] peptide.
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Scheme S7. The synthesis of monocyclic F-[KW4E] peptide.
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Scheme S8. The synthesis of fluorescein-labeled bicyclic peptide F-[KW4E]-(β-Ala)[KR5].
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ABSTRACT
The majority of the reported arginine-rich cell-penetrating peptides (CPPs) for the
enhanced delivery of drugs are linear peptides. Moreover, they are usually composed
of more than seven arginine residues to retain the cell penetration properties. Herein,
we synthesized a class of eight polyarginine peptides containing 5 and 6 arginines
namely R5 and R6. We further explored the effect of acylation with long chain fatty
acids (i.e., octanoic acid, dodecanoic acid, hexadecanoic acid), and cyclization of
amino acids on the cell penetrating properties of the peptides. The fluorescencelabeled acylated cyclic peptide dodecanoyl-[R5] and linear peptide dodecanoyl-(R5)
showed approximately 13.7- and 10.2-fold higher cellular uptake than that of control
5(6)-carboxyfluorescein, respectively. The mechanism of the peptide internalization
into cells was found to be energy-dependent endocytosis. The molecular transporter
ability of fatty acylated cyclic peptides was evaluated using a flow cytometry method.
Dodecanoyl-[R5] and dodecanoyl-[R6] enhanced the intracellular uptake of a
fluorescence-labeled cell impermeable negatively charged phosphopeptide (F′GpYEEI) in human ovarian cancer cells (SK-OV-3) by 3.4-fold and 5.5-fold,
respectively. The cellular uptake of F′-GpYEEI in the presence of hexadecanoyl-[R5]
was 9.3- and 6.0-fold higher than that of in the presence of octanoyl-[R5] and
dodecanoyl-[R5], respectively. A comparative FACS results showed that dodecanoyl[R5] enhanced the cellular uptake of the phosphopeptide by 1.4-2.5 fold higher than
the corresponding linear peptide dodecanoyl-(R5) and those of representative CPPs,
such as hepta-arginine (CR7) and TAT peptide. Our findings showed that a
combination of acylation by long chain fatty acids and cyclization on short arginine-
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containing peptides can improve their cell-penetrating property, possibly through
efficient interaction of rigid positively charged R and hydrophobic dodecanoyl moiety
with the corresponding residues in the cell membrane phospholipids.

Keywords: Acylation, Cyclic Peptide, Cyclization, Drug Delivery, Polyarginine.
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INTRODUCTION
Polyarginine peptides are known as one of the widely used classes of cellpenetrating peptides (CPPs) and cellular delivery tools.1 It has been reported that the
presence of the guanidine group in the side chain of arginine plays a key role for
improved ability of arginine-rich peptides to cross the cell membrane.2,3 Various
systematic structural investigations have been performed to determine the required
number of arginine residues and the length of the peptide for the optimization of
cellular uptake.2,4 Short polyarginine peptides containing less than six arginine
residues did not exhibit significant cellular uptake in several previously reported
investigations.2,4,5 Thus, the presence of more than six arginine residues in the
structure of polyarginine peptides is critical for their efficient cell-penetrating
functions.
On the other hand, several investigations were conducted to increase the cellular
uptake of polyarginines by attaching the fatty acid to the N-terminal of the peptide. It
has been previously reported that the acylation of the N-terminal by fatty acids can
facilitate the intracellular uptake of polyarginines.6–8 For instance, Katayama et al.
synthesized acylated octa-arginines and discovered that the introduction of
hydrophobic fatty acid enhanced the intracellular uptake of octa-arginine peptide and
its conjugated ubiquitin.8 Furthermore, Lee et al. designed a class of lipopeptides
carrying 7-15 arginine residues. Among them, myristoylated-hendeca-arginine
(C14R11) was found to be the most efficient cell-penetrating peptide.7 However, the
fatty acylated polyarginine peptides that contain 7-15 arginine residues can potentially
cause toxicity, and they can be easily degraded by proteases.
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Moreover, linear peptides carrying L-form are not stable in serum and therefore
have a limited application for in vivo studies.9 Replacing L-form amino acids with Dform to improve the peptide stability leads to high cost production. On the other hand,
cyclic peptides show more proteolytic stability than linear counterparts. Thus, the
synthesis and development of cyclic CPPs containing short amino acid sequence with
less toxicity is desired.
Herein, we designed acylated cyclic polyarginine peptides (ACPPs) containing
five arginine residues and investigated their ability as cell-penetrating peptides. We
compared ACPPs with a corresponding acylated linear polyarginine peptide (ALPP)
and a nonacylated cyclic polyarginine as controls. We hypothesize that the
combination of acylation and cyclization of short polyarginine peptides having less
than six arginine residues will increase the intracellular uptake and can generates
peptides with molecular transporter properties. For convenience, square brackets [ ]
and parentheses ( ) were used to represent cyclic and linear peptides, respectively.

EXPERIMENTAL SECTION
Peptide Synthesis. All peptides were synthesized by Fmoc/tBu solid-phase peptide
synthesis strategy either manually or using Rainin PS3™ synthesizer (Protein
Technologies Inc.). Manual reactions were carried out in a glass reaction vessel with a
sintered glass frit by mixing under nitrogen bubbling at room temperature. Fmoc-Lamino acid building blocks, fatty acids, and single Arg(Pbf) loaded 2-chlorotrityl resin
were used as starting materials. 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate

(HBTU),

hydroxybenzotriazole
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(HOBT),

and

N,N-

diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) were used as
coupling and activating reagents, respectively for manual synthesis. In case of using
peptide synthesizer, 0.4 M N-methylmorpholine in DMF was used instead of DIPEA.
Piperidine in DMF (20%) was employed to deprotect Fmoc group at each step.
To cleave the linear peptide from the resin, a mixture of trifluoroacetic acid
(TFA)/triisoproylsilane (TIS)/water (92.5/5/2.5, v/v/v) was used. However, in the
synthesis of cyclic peptides, the side chain protected linear peptides were first cleaved
from the resin by using a cleavage cocktail, containing 2,2,2-trifluoroethanol
(TFE)/acetic acid/dichloromethane (DCM) (2:1:7, v/v/v). Cyclization reaction was
performed by employing a mixture of 1-hydroxy-7-azabenzotriazole (HOAT) and
N,N-diisopropylcarbodiimide (DIC) in anhydrous DMF/DCM for 12 h. After solvent
evaporation, the peptide was deprotected and cleaved from the resin by using a
cleavage

cocktail

reagent

″R″,

containing

TFA/thioanisole/1,2-ethanedithiol

(EDT)/anisole (90:5:3:2, v/v/v/v) for 2-3 h. The crude peptides were precipitated and
washed with cold diethyl ether. To purify the crude peptides, we used a reversed-phase
high pressure liquid chromatography (RP-HPLC) system using Shimadzu LC-8A
preparative liquid chromatography on a Phenomenex Gemini C18 column (10 μm,
250 × 21.2 mm) with a gradient 0-100% of acetonitrile (CH3CN) containing 0.1%
TFA (v/v) and water containing 0.1% TFA (v/v) for 1 h with a flow rate at 15.0
mL/min at the wavelength of 214 nm.
As a representative example, the synthesis of dodecanoyl-[R5] is described here.
H-Arg(Pbf)-2-chlorotrityl resin (660 mg, 0.35 mmol, 0.53 mmol/g) was swelled in
DMF for 40 min by N2. Fmoc-Arg(Pbf)-OH (681 mg, 1.05 mmol, 3 equiv) was
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coupled to the N-terminal of the resin, using HBTU (398 mg, 1.05 mmol, 3 equiv),
HOBT (142 mg, 1.05 mmol, 3 equiv), and DIPEA (366 µL, 2.1 mmol, 6 equiv) in
DMF (15 mL) by agitating the resin for 1 h using N2. After the coupling, the resin was
washed with DMF, followed by Fmoc-deprotection with piperidine in DMF (20%).
The subsequent three Fmoc-Arg(Pbf)-OH couplings and one Dde-Lys(Fmoc)-OH
(559 mg, 1.05 mmol, 3 equiv; Dde = 1-(4,4-dimethyl-2,6-dioxocyclohex-1ylidene)ethyl) coupling was carried out in the same manner, respectively. After
removing the Fmoc group in side chain of lysine, dodecanoic acid (210 mg, 1.05
mmol, 3 equiv) was coupled using HBTU, HOBT, and DIPEA. Then Dde protection
group at N-terminal of peptide was removed by 2% hydrazine in DMF, followed by
washing with DMF and DCM. The side chain protected linear peptides were cleaved
from the resin by using a cleavage cocktail, TFE/acetic acid/DCM (2:1:7, v/v/v) for 1
h. The filtrate was evaporated, and the residue was dried overnight in a vacuum. The
cyclization was conducted under a dilute condition with anhydrous DMF/DCM (5:3,
v/v, 250 mL), using HOAT (190 mg, 1.4 mmol, 4 equiv) and DIC (240 μL, 1.54
mmol, 4.4 equiv), and stirred for 12 h under nitrogen atmosphere. After cyclization,
the solvent was evaporated, and the side chain deprotection was carried out by the
addition of reagent ″R″ for 2 h. The crude dodecanoyl-[R5] was precipitated and
washed with cold diethyl ether, and purified by preparative RP-HPLC system as
described above.
Fluorescein-labeled peptides were synthesized with the same protocol before the
attachment of fatty acid. We used Fmoc-12-aminododecanoic acid instead of
dodecanoic acid, and after removing Fmoc group, 5(6)-carboxyfluorescein
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diisobutyrate

(CFDI)

was

attached

using

7-azabenzotriazol-1-yl-

oxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP), HOAT, and DIPEA.
As an example, we started fluorescein-labeled peptide synthesis in smaller scale with
H-Arg(Pbf)-2-chlorotrityl resin (208 mg, 0.11 mmol, 0.53 mmol/g). Fmoc-Arg(Pbf)OH (214 mg, 0.33 mmol, 3 equiv), Dde-Lys(Fmoc)-OH (176 mg, 0.33 mmol, 3
equiv), and Fmoc-12-aminododecanoic acid (144 mg, 0.33 mmol, 3 equiv) were used
to couple each building block to the resin using HBTU (125 mg, 0.33 mmol, 3 equiv),
HOBT (45 mg, 0.33 mmol, 3 equiv), and DIPEA (115 µL, 0.66 mmol, 6 equiv) in
DMF. CFDI (170 mg, 0.33 mmol, 3 equiv) was coupled with amino group of 12aminododecaonic chain using PyAOP (172 mg, 0.33 mmol, 3 equiv), HOAT (45 mg,
0.33 mmol, 3 equiv), and DIPEA. The reaction mixture was agitated for 3 h using N2.
After removal of Dde protecting group with 2% hydrazine in DMF and washing with
DMF and DCM, side chain protected fluorescein linear peptides were cleaved from
resin using TFE/acetic acid/DCM (2:1:7, v/v/v). The following cyclization and
purification steps were same as above. The molecular weights of final products were
confirmed by an AXIMA performance matrix-assisted laser desorption/ionization-time
of flight (MALDI-TOF) mass spectrometer (Shimadzu Corporation).

Dodecanoyl-[R5]: MALDI-TOF (m/z): C48H94N22O7 calcd. 1090.7676; found
1091.7576 [M + H]+. Dodecanoyl-[R6]: MALDI-TOF (m/z): C54H106N26O8 calcd.
1246.8687; found 1247.7397 [M + H]+. Dodecanoyl-(R6): MALDI-TOF (m/z):
C48H96N22O8 calcd. 1108.7781; found 1109.7308 [M + H]+. [R5]: MALDI-TOF (m/z):
C36H72N22O6 calcd. 908.6005; found 909.6772 [M + H]+. F′-Dodecanoyl-[R5]:
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MALDI-TOF (m/z): C69H105N23O13 calcd. 1463.8262; found 1464.6556 [M + H]+. F′Dodecanoyl-(R5): MALDI-TOF (m/z): C69H107N23O14 calcd. 1481.8368; found
1482.7586 [M + H]+. W-Dodecanoyl-[R5]: MALDI-TOF (m/z): C61H107N25O9 calcd.
1333.8684; found 1334.8713 [M + H]+. W4-[R5]: MALDI-TOF (m/z): C82H114N30O11
calcd. 1694.9283; found 1696.3111 [M + H]+. Octanoyl-[R5]: MALDI-TOF (m/z):
C44H86N22O7 calcd. 1034.7050; found 1035.7084 [M + H]+. Hexadecanoyl-[R5]:
MALDI-TOF (m/z): C52H102N22O7 calcd. 1146.8302; found 1147.8404 [M + H]+.

Cell Culture. Human ovarian adenocarcinoma (SK-OV-3), leukemia (CCRF-CEM),
and embryonic kidney (HEK 293T) cells were purchased from American Type Culture
Collection. The SK-OV-3 and HEK 293T cells were grown in eagle’s minimum
essential medium (EMEM), and RPMI-1640 medium (ATCC, Manassas, VA) was
used for CCRF-CEM cells. Both medium were supplemented with fetal bovine serum
(FBS, 10%) and penicillin-streptomycin solution (1%, 10,000 units of penicillin and
10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% CO2 at 37 °C.

Cytotoxicity Assay. Cytotoxicity of peptides was examined by MTS proliferation
assay in two human cancer cell lines (SK-OV-3 and CCRF-CEM) and one human
normal cell line (HEK 293T). Cells were seeded into 96-well plates (SK-OV-3 (5 ×
103 cells/well), CCRF-CEM (1 × 105 cells/well), and HEK 293T (1 × 104 cells/well)).
Then, the cells were incubated with complete media (100 µL) for overnight. Different
concentration (0–600 µL) of peptide solution (10 µL) were added to cells and
incubated at 37 C with 5% CO2 for 24 h. Then, CellTiter 96 aqueous solution (20 µL)
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was added to each well and incubated for 1-4 h. The absorbance was measured at 490
nm using microplate reader. The cells without any peptide were used as the control.

Flow Cytometry
Cellular Uptake of Fluorescein-Labeled Peptide. SK-OV-3 cells were grown in 6well plates (2 × 105 cells/well) with complete EMEM media 24 h prior to the
experiment. The fluorescein-labeled peptide stock solution (1 mM) was prepared in
water and diluted in Gibco® Opti-MEM® I reduced serum medium to obtain the final
concentration of 5 M. The media were removed and the mixture containing
fluorescein-labeled peptide solution (5 M) was added. After 1 h incubation, trypsinEDTA solution was added to detach cells from plate’s surface and remove cell surface
binding peptides. After 5 min, the complete media (2 mL) was added to neutralize the
trypsin. The cells were collected and centrifuged at 2500 rpm for 5 min. Then they
were washed with PBS (without calcium and magnesium) twice. Samples were
prepared in FACS buffer for analysis. Finally, the cells were analyzed by BD
FACSCalibur™ or FACSVerse™ flow cytometer using FITC channel. The data
collection was based on the mean fluorescence signal for 10,000 cells. All assays were
carried out in triplicate. 5(6)-Carboxyfluorescein (FAM) was used as a negative
control.

Mechanism Study of Cellular Uptake by Removing Energy Sources. For
examination of the cellular uptake mechanism of F′-dodecanoyl-[R5] at low
temperature, the assay was carried out at 4 °C to inhibit the energy-dependent cellular
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uptake pathways. The SK-OV-3 cells were preincubated at 4 °C for 15 min and
incubated with the fluorescein-labeled peptide for 1 h at 4 °C. Cells were collected and
analyzed using flow cytometry with the previously described protocol above. The data
collected at 37 °C were used as the control. To perform the ATP-depletion assay, cells
were incubated with sodium azide (10 mM) and 2-deoxy-D-glucose (50 mM) for 1 h
before adding the fluorescein-labeled peptide. During the incubation time (1 h), the
fluorescein-labeled bicyclic peptide (5 M) was prepared in the Opti-MEM® I
reduced serum medium in the presence of sodium azide (10 mM) and 2-deoxy- Dglucose (50 mM). Then, the cells were incubated with this solution for 1 h. The
following sample preparation and flow cytometry analysis protocol was same as
described above.

Confocal Laser Scanning Microscopy (CLSM). SK-OV-3 cells were seeded with
complete EMEM on coverslips in 6-well plate (1 × 105 cells/well) and kept until 50%
confluency. The media were removed, and cells were incubated with F′-dodecanoyl[R5] (10 M) and F′-dodecanoyl-(R5) (10 M) in Gibco® Opti-MEM® I reduced
serum medium (Life Technologies, Grand Island, NY) for 1 h at 37 C. Then cells
were washed with 1 × phosphate buffered saline with calcium and magnesium (PBS+)
for three times. The coverslips were mounted on microscope slides, and images were
obtained using Carl Zeiss LSM 700 system with a 488 nm argon ion laser excitation
and a BP 505-530 nm band pass filter.
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Intracellular Uptake of a Phosphopeptide, F-GpYEEI. SK-OV-3 and CCRF-CEM
cells were seeded in 6-well plates (2 × 105 cells/well for SK-OV-3 and 1 ×
106cells/well for CCRF-CEM) and grown with complete EMEM media (RPMI-1640
for CCRF-CEM) for overnight. A mixture of fluorescein-labeled phosphopeptides FGpYEEI (5 M) and peptides (10 M) were prepared in OPTI-MEM I® reduced
serum medium at room temperature and incubated for 15 min. Then the cells were
incubated with the premixed solution at 37 C with 5% CO2 for 1 h. The sample
preparation for FACS analysis was carried out by previously mentioned protocol
described before. In this assay, DMSO and F-GpYEEI were used as the negative
controls.

RESULTS AND DISCUSSION
Chemistry
The acylated cyclic polyarginine peptides were synthesized by Fmoc/t-Bu solidphase peptide synthesis method. Fmoc-L-Arg(Pbf)-OH was coupled on H-Arg(Pbf)
loaded 2-chlorotrityl resin in the presence of HBTU, HOBT, and DIPEA in DMF.
Then Dde-Lys(Fmoc)-OH was attached, and a fatty acid was coupled to the side chain
of lysine. Dde protecting group was removed by 2% hydrazine in DMF, and a
cleavage cocktail containing TFE/acetic acid/DCM (2:1:7 v/v/v) was used for 1 h to
cleave the side-chain protected linear peptides from the resin. Cyclization of linear
peptides was carried out in the presence of a mixture of HOAT and DIC in anhydrous
DMF/DCM for 6-24 h. The side-chain deprotection of cyclic peptide were carried out
by a cleavage cocktail reagent ″R″ for 2 h. The crude peptides were precipitate and
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purified with RP-HPLC as described above. As a representative example, the synthesis
of dodecanoyl-[R5] is shown in Scheme 1.
A corresponding acylated linear polyarginine peptide (ALPP) was synthesized for
comparative studies with the cyclic peptide (ACPP). Moreover, a cyclic polyarginine
without fatty acid [R5] was also synthesized to investigate the effect of the fatty acid
on cyclic peptide and its effect on molecular transporting efficiency. To investigate
whether the peptide alone can enter into cells, fluorescein-labeled F′-dodecanoyl-[R5],
and F′-dodecanoyl-(R5), where F = fluorescein, were synthesized for FACS and
microscopy investigations. All synthesized peptides are shown in Figure 1.

Cytotoxicity Assay of Synthetic Peptides
The cytotoxicity of all peptides were tested in two different cancer cell lines,
adherent (SK-OV-3) and non-adherent (CCRF-CEM) cells and a normal cell line
(HEK 293T) using MTS assay (Figure 2). Cyclic polyarginine [R5] without fatty acid
was used to explore the effect of N-terminal acylation on cytotoxicity and cellular
uptake. ALPP (dodecanoyl-(R5)) and [R5] peptides showed consistently less
cytotoxicity in all three cells compared to ACPPs (dodecanoyl-[R5] and dodecanoyl[R6]). After 24 h incubation, ACPPs showed approximately 20% toxicity in cells at a
concentration of 25 µM in CCRF-CEM cells. However, linear dodecanoyl-(R5) and
cyclic [R5] did not exhibit significant cytotoxicity at 25 µM and showed less than 20%
toxicity at the concentration of 100 µM. In SK-OV-3 cells, dodecanoyl-(R5) and [R5]
showed more than 80% cell viability at the concentration of 25 µM. In normal cells
(HEK 293T), all peptides exhibited less than 5% toxicity at 25 µM. This differential
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behavior of the peptides in normal and cancer cells can be possibly rationalized
through the interaction between polyarginine peptides and cell membranes. The
membrane of cancer cells holds more negative charges compared to that in normal
cells because of the presence of anionic lipids such as phosphatidylserine.10 Therefore,
polyarginine peptides can be interacted with cancer cells more effectively compared to
normal cells. Consequently, higher cell viability was observed in normal cells. These
data indicated that ACPPs are more toxic than ALPP and a non-acylated cyclic peptide
[R5], especially at concentration of ≥25 µM. Thus, a non-cytotoxic concentration of 510 µM was used in cell-based assays.

Cellular Uptake of Fluorescein-labeled Acylated Cyclic and Linear Polyarginine
Peptides
The intracellular uptake studies of fluorescein-labeled acylated cyclic and linear
PP, F′-dodecanoyl-[R5] and F′-dodecanoyl-(R5), was carried out in SK-OV-3 cells by
using flow cytometry and confocal laser scanning microscopy (CLSM) methods.
Fluorescein (FAM, F′) alone was selected as a negative control. As it is shown in
Figure 3, The F-dodecanoyl-[R5] and F-dodecanoyl-(R5) showed approximately 13.7and 10.3-fold higher cellular uptake than that of control 5,6-carboxyfluorescein
(FAM), respectively, in SK-OV-3 cells. F′-dodecanoyl-[R5] showed 1.3-fold higher
cellular uptake compared to that of F′-dodecanoyl-(R5). The cellular uptake of F′dodecanoyl-[R5] was confirmed by CLSM images (Figure 4). F′-Dodecanoyl-[R5]
showed higher fluorescence intensity compared to that of F′-dodecanoyl-(R5) in SKOV-3 cells. Therefore, ACPP F′-dodecanoyl-[R5] was found to be more efficient cell-
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penetrating peptide compared to the linear counterpart. As shown in Figure 4, the
fluorescence signal is extended through the whole cells, suggesting that F′dodecanoyl-[R5] can get localized in the nucleus as well as cytoplasm.

Cellular Uptake Mechanistic Study of F′-Dodecanoyl-[R5]
The mechanism of the cellular internalization of F′-dodecanoyl-[R5] was
investigated by a temperature control assay at 4 °C along with ATP depletion assay.
These two assays have been widely used to examine the energy-dependent
endocytosis.11 FACS results showed that the intracellular uptake of F′-dodecanoyl[R5] was significantly reduced at 4 °C, indicating that the mechanism of
internalization was mainly dependent on the endocytosis pathways (Figure 5).12
Furthermore, ATP depletion assay was performed to investigate receptor-mediated
endocytosis.13 To induce ATP depletion, SK-OV-3 cells were pre-incubated with
sodium azide (10 mM) and 2-deoxy-D-glucose (50 mM) for 1 h prior to the
experiment, and a similar concentration was maintained during the incubation (1 h)
with F′-dodecanoyl-[R5]. The results showed that the cellular uptake of F′-ACPP was
inhibited in the presence of sodium azide and 2-deoxy-D-glucose, suggesting that
receptor-mediated endocytosis is involved for the cellular uptake of F′-ACPP. In ATP
depletion assay, the basic cellular uptake of FAM was higher compared to that in
temperature control assay. However, this is evident that the intracellular uptake of F′dodecanoyl-[R5] was inhibited, and there was no significant difference between the
cells treated with FAM compared to those treated with F′-dodecanoyl-[R5] in
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temperature control and ATP depletion assays, suggesting that endocytosis is the
major pathway for the cellular uptake of F′-dodecanoyl-[R5].14

Molecular Transporter Property of Peptides
The ability of ACPPs as a molecular transporter was evaluated and compared by
selecting a fluorescein-labeled phosphopeptide, F′-GpYEEI, as a molecular cargo. The
phosphopeptide, pYEEI (pTyr-Glu-Glu-Ile) is an optimal peptide template for the SH2
domain of Src tyrosine kinase. Several analogues of this peptide have been
synthesized as potent ligands for this target.15–17 Due to the presence of the negatively
charged amino acid residues in the structure of the phosphopeptide including
phosphorylated tyrosine, it does not cross the cell membrane easily. Moreover, the
internalization of the negatively charged phosphopeptide in cancer cells by diffusion is
more difficult because cancer cell membranes are composed of more negatively
charged lipids. Thus, cellular delivery of cell-impermeable negatively charged
phosphopeptides is significantly challenging. We have previously reported different
peptide-based carriers for the intracellular delivery of negatively charged
phosphopeptides as model cell-impermeable drugs in several cell lines.18
In this study, the intracellular uptake of F′-GpYEEI was monitored in the
presence and absence of synthetic peptides after 1 h incubation by flow cytometry. As
it is exhibited in Figure 6, the ACPPs (dodecanoyl-[R5] and dodecanoyl-[R6])
delivered the phosphopeptide more efficiently compared to ALPPs, dodecanoyl-(R5)
and [R5]. The intracellular uptake of F′-GpYEEI in the presence of dodecanoyl-[R5]
and dodecanoyl-[R6] was enhanced by 3.4- and 5.5-fold higher than the uptake in the
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absence of ACPPs. However, dodecanoyl-(R5) and [R5] only improved 1.3- and 1.4fold intracellular uptake, respectively. The results showed that acylated and cyclized
polyarginine peptides can deliver the phosphopeptide effectively. However, the
intracellular uptake of the phosphopeptide did not improve significantly in the
presence of either acylated linear polyarginine peptide or cyclic [R 5]. These data
suggest that a combination of acylation and cyclization would improve the molecular
transporting efficiency of the polyarginine-based peptide (containing less than six
arginines) for the intracellular delivery of a cell-impermeable phosphopeptide. It has
been previously reported that the acylated linear octa-arginine increased the cellular
uptake of molecular cargoes by just adding fatty acid to the N-terminal of octaarginine.8 However, we discovered that both cyclization and acylation in a short pentaarginine can significantly improve the delivery of a cell-impermeable phosphopeptide
in SK-OV-3 cells.
The major driving forces for the intracellular delivery are presumed to be
structural rigidity through cyclization of the peptide and the interaction of the fatty
acid with the cell membrane. It has been previously reported that the cellular uptake of
the peptide can be increased due to the structural rigidity by cyclization of argininerich peptides.3 They proposed that the maximal distance between guanidine groups of
arginine residue can lead to an efficient transduction of arginine-rich peptides. Our
investigations showed that dodecanoyl-[R6] is able to deliver more efficiently by 1.6fold higher F′-GpYEEI uptake compared to that of dodecanoyl-[R5]. Increasing the
number of positively charged arginine residues can enhance the cellular uptake
through ionic interactions with the negatively charged phosphopeptide and/or
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phospholipid in the cell membrane through ionic interactions. However, the higher
number of arginine residue is not the only responsible element for the efficient cellular
internalization. For example, it has been reported that polyarginine containing eleven
amino acids (R11) showed higher cellular uptake compared to the polyarginine
containing thirteen amino acids (R13). At the same time, R11 was found to be more
potent transporter compared to R9 in prostate cancer cells.19 These investigations
showed that an optimal number of arginine residues are required for the highest degree
of functionality. However, the more number of amino acid residues in cyclic peptides
can decrease the structural rigidity, which lower the ability of the peptide to get into
cells.
Dodecanoyl-[R5] was also compared with several commonly CPPs, such as CR7
and TAT (YGRKKRRQRRR) peptides. The ACPP improved the cellular uptake of
the phosphopeptide by 1.4- and 1.8-fold higher than those of CR7 and TAT,
respectively (Figure 6B). Thus, these results revealed that ACPP dodecanoyl-[R5] can
be used as an efficient molecular transporter even it has shorter peptide sequence than
CR7 and TAT.

The Effect of Fatty Acid Chain Length on the Cellular Uptake of ACPPs
To investigate the effect of the chain length on the cell penetration potency, we
synthesized octanoyl-[R5], dodecanoyl-[R5], and hexadecanoyl-[R5] (Figure 8). The
cytotoxicity of the peptides was examined in SK-OV-3 cells. ACPPs showed less than
20% toxicity in cells at the concentration of 25 µM. The in vitro toxicity results
showed that increasing the fatty acid chain length caused enhanced toxicity in cells as

61

hexadecanoyl-[R5] was more cytotoxic than dodecanoyl-[R5] and octanoyl-[R5]. These
data indicate that the fatty acid chain length could alter the interaction with the cell
membrane and disturb the membrane integrity. Based on the cytotoxicity data, a
concentration of 10 µM was selected for further cell-based assays.
It has been previously reported that there was a relationship between the length of
fatty acid in polyarginines and their cellular uptake,7 meaning that the optimal length
of fatty acid is required for optimal functionality based on the peptide sequence and
cell type. The results exhibited that the cellular uptake of F′-GpYEEI was improved in
the order of octanoyl-[R5] < dodecanoyl-[R5] < hexadecanoyl-[R5]. The cellular
uptake of F′-GpYEEI in the presence of hexadecanoyl-[R5] was 9.3- and 6.0-fold
higher than that of in the presence of octanoyl-[R5] and dodecanoyl-[R5], respectively.
These data suggest that among the synthesized peptides, hexadecanoyl-[R5] containing
a fatty acid with sixteen-carbon chain length (C16) is an optimized length for the
intracellular delivery of F′-GpYEEI in SK-OV-3 cells.

Effect of Addition of Tryptophan Residues in Molecular Transporter Property
After ACPPs were found to act as CPP and molecular transporter, a systematic
investigation was performed to modify the fatty acid to another hydrophobic moiety.
Two other conjugates were synthesized. In the first conjugate, W4-[R5], the whole
fatty acid chain was replaced with four tryptophan residues. The second conjugate Wdodecanoyl-[R5] had one more tryptophan at the end of the dodecanoyl fatty acid
chain. W4-[R5] enhanced intracellular delivery of F-GpYEEI by 4.1-fold higher
compared to that of dodecanoyl-[R5] in SK-OV-3. However, W-dodecanoyl-[R5]
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improved the uptake of F′-GpYEEI by 1.3-fold higher compared to that of W4-[R5] in
CCRF-CEM cells (Figure 9). The cellular uptake is affected by the cell lines. Thus, it
is not straightforward to compare the cellular uptakes in SK-OV-3 and CCRF-CEM.
However, the results could be assessed indirectly by relative comparison with the
cellular uptake by W4-[R5]. These data suggest that the presence of hydrophobic
tryptophan moieties could enhance the molecular transporting efficiency. In other
words, appropriate modification of hydrophobic moiety in CPPs can increase the drug
delivery ability of ACPP. Existing a balance between the cyclization of short
polyarginine and the presence of hydrophobic moiety is critical to obtain the optimal
intracellular transportation ability.

CONCLUSION
In conclusion, acylated cyclic polyarginine peptides were synthesized and
examined as CPPs and potential molecular transporters. ACPPs showed higher
potency as molecular transporter compared to the corresponding linear counterpart and
cyclic polyarginine without fatty acid. The mechanism of the peptide internalization
was found to be energy-dependent endocytosis. Cyclization and acylation reactions on
the structure of the peptide enhanced the intracellular uptake of polyarginine peptides
although they carry a short length of sequence. This intracellular delivery property of
ACPPs can be optimized by modifying the length of fatty acid chain. To the best of
our knowledge, this is the first report of fatty acylated cyclic polyarginine peptide as
molecular transporter of a cell-impermeable phosphopeptide. This study provided
insights about how a combination of the cyclic nature and acylation can improve the
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cell internalization of polyarginines. Further investigations are undergoing to
determine whether conjugation of cell-impermeable hydrophobic drugs to acylated
cyclic polyarginines can be an efficient method for designing novel drug delivery
systems.
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ABBREVIATIONS
ACPP, acylated cyclic polyarginine peptides; ALPP, acylated linear polyarginine
peptide; ATP, adenosine triphosphate; CCRF-CEM, human leukemia carcinoma cell
line; CFDI, 5(6)-carboxyfluorescein diisobutyrate; CLSM, confocal laser scanning
microscopy; CPPs, cell-penetrating peptides; DCM,

dichloromethane; Dde, 1-(4,4-

dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl;

N,N-diisopropylcarbodiimide;

DIC,

DIPEA, N,N-diisopropylethylamine; DMF, N,N-dimethylformamide; EDT, 1,2ethanedithiol;

EMEM,

eagle’s

minimum

essential

medium;

FAM,

5(6)-

carboxyfluorescein; FBS, fetal bovine serum; Fmoc, 9-fluorenylmethoxycarbonyl;
FACS, fluorescence activated cell sorter; HBTU, 2-(1H-Benzotriazole-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate; HEK 293T, human embryonic kidney cell
line; HOAT, 1-hydroxy-7-azabenzotriazole; HOBT, hydroxybenzotriazole; MALDITOF, matrix-assisted laser desorption/ionization-time of flight; MTS, (3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium); NMP, N-methylmorpholine); PBS, phosphate buffered saline; PyAOP,
7-azabenzotriazol-1-yl-oxytris(pyrrolidino)phosphonium hexafluorophosphate; RPHPLC, reversed-phase high pressure liquid chromatography; SK-OV-3, human
ovarian adenocarcinoma cell line; TFA, trifluoroacetic acid; TFE, 2,2,2trifluoroethanol ; TIS, triisoproylsilane.
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Figure legends
Figure 1: Chemical structures of synthetic peptides used in this study. (F′: fluoresceinlabeled; [ ]: cyclic peptide; ( ): linear peptide)
Figure 2: Comparison of cytotoxicity between cyclic and linear acylated polyarginine
peptides, and non-acylated cyclic peptide [R5] at various concentrations against
CCRF-CEM, SK-OV-3, and HEK 293T after 24 h.
Figure 3: Comparative cellular uptake of F′-dodecanoyl-[R5] and F′-dodecanoyl-(R5)
(5 µM) in SK-OV-3 cells (1 h).
Figure 4: Confocal laser scanning microscope image of (A) F′-dodecanoyl-[R5] and
(B) F′-dodecanoyl-(R5). The peptides were incubated for 1 h in SK-OV-3 cells at 10
µM concentration.
Figure 5: Cellular uptake of F′-dodecanoyl-[R5] (5 µM) in SK-OV-3 cells in
temperature control assay at 37 °C and 4 °C, and ATP depletion assay with NaN3 (10
mM) and 2-deoxy-D-glucose (50 mM) analyzed by flow cytometry.
Figure 6: Cellular uptake of F΄-GpYEEI (5 µM) in the presence of dodecanoyl-[R5],
[R5], dosecanoyl-(R5), and dodecanoyl-[R6] (10 µM) in SK-OV-3 cell line.
Phosphopeptide delivery efficiency of dodecanoyl-[R5] were compared with known
CPPs (R7: CRRRRRRR; TAT: YGRKKRRQRRR). The mean fluorescence of F΄GpYEEI taken by dodecanoyl-[R5] was set as 100%.
Figure 7: Chemical structures of ACPPs with different length of fatty acid chains (C8,
C12, and C16).
Figure 8: (A) Cytotoxicity assay of cyclic polyarginine peptide-fatty acid conjugates
against SK-OV-3 cells (24 h incubation). (B) Cellular uptake of a phosphopeptide, F′-
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GpYEEI (5 μM) in the presence of peptide-fatty acid conjugates (10 μM) in SK-OV-3
cells.
Figure 9: Cellular uptake assay of a phosphopeptides, F′-GpYEEI (5 μM) in the
presence of W4-[R5] and W-dodecanoyl-[R5] (10 μM) against SK-OV-3 and CCRFCEM cell lines (1 h incubation). The mean fluorescence of F′-GpYEEI by W4-[R5]
was set as 100%.

Scheme legends
Scheme 1. Synthesis of dodecanoyl-[R5] as a representative example.
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ABSTRACT
Multidrug resistant pathogens have become a major public health concern. There
is a great need for the development of novel antibiotics with alternative mechanisms of
action the treatment of life-threatening bacterial infections. Antimicrobial peptides
(AMPs), a major class of antibacterial agents, share amphiphilicity and cationic
structural properties with cell-penetrating peptides (CPPs). We have previously
reported that a number of amphiphilic cyclic peptides have enhanced cellular uptake
properties in eukaryotic cells versus their linear counterparts. Herein, several
amphiphilic cyclic CPPs and their analogs were synthesized and exhibited potent
antibacterial activities against multidrug resistant pathogens. Among them, cyclic
peptide [R4W4] (peptide 1) showed the most potent antibacterial activity against
methicillin-resistant Staphylococcus aureus (MRSA, exhibiting a minimum inhibitory
concentration (MIC) of 2.67 µg/mL). Cyclic [R4W4] and the linear counterpart R4W4
exhibited MIC values of 42.8 and 21.7 µg/mL, respectively, against Pseudomonas
aeruginosa. [R4W4] in combination with tetracycline enhanced the potency, by
decreasing the MIC 4 fold (0.12 µg/mL) presenting partial synergistic effect of the
combination between peptide 1 and tetracycline against MRSA. Twenty-four hour
time-kill studies evaluating [R4W4] with 2× the MIC in combination with tetracycline
demonstrated bactericidal activity at 4 and 8× the MIC of tetracycline against MRSA
and 2-8× the MIC against E. coli, respectively. Peptide 1 presented its cell-penetrating
properties as expected, and showed more than 84% cell viability at 15 µM (20.5
µg/mL) concentration against in three different human cell lines. This study suggests
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that amphiphilic cyclic CPPs, when used in combination with antimicrobials may
provide additional benefit to defeat multi-drug resistant pathogens.

Keywords: Antimicrobial Peptide, Cell-Penetrating Peptide, Combination, Drug
Delivery, MRSA.
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INTRODUCTION
The emergence of Methicillin-resistant Staphylococcus aureus (MRSA) threatens
public health worldwide. Despite a half century of efforts to find effective treatments,
healthcare practitioners are still challenged to cure infections caused by MRSA.1
MRSA is widespread in hospitals, and community-associated MRSA has continued to
emerge since the mid-1990s.2 In 2009, 463,017 infections were attributed to MRSA,
which corresponds to 11.74 infections per 1,000 hospitalizations in the United States.3
Approximately 19,000 of human death were attributed to invasive MRSA in 2005. 4
Moreover, MRSA rapidly evolves resistance against new commercial antibiotics.
Currently, vancomycin is employed commonly for the treatment of MRSA.
However, vancomycin-resistant Staphylococcus aureus was reported in 1996.5
Daptomycin is a cyclic lipopeptide having a broad spectrum against Gram-positive
bacteria, and it shows fast antibacterial responses. Its novel mechanism of action
involves membrane depolarization resulting in efflux of potassium ions, followed by
bacterial cell death.6 Despite its novelty of the mechanism, daptomycin-resistance by
MRSA was reported in 2005, only two years after FDA approval. The resistance
mechanism against daptomycin remains to be determined.7 Thus, new classes of
antibiotics with different mechanisms of action are urgently needed.
Antimicrobial peptides (AMPs) have emerged as alternative therapeutics against
antibiotic resistant pathogens because they can act as effectors and regulators of the
immune system as well as inhibitors of bacterial cell growth.8 Cationic AMPs target
negatively charged bacterial membrane lipids, which may reduce the occurrence of
bacterial resistance.9 AMPs have been found as host defense peptides in various
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organisms, such as insects, amphibians, and mammalians.10,11 AMPs such as magainin
and omiganan are in clinical trials or in development.12
Cell-penetrating peptides (CPPs) are short hydrophilic and/or amphiphilic
peptides. Because of their ability to translocate across the eukaryotic cell membrane,
they have been studied as molecular vehicles to deliver other drugs inracellularly.13,14
Some AMPs and CPPs share similar physical properties, such as amphiphilicity and
cationic properties. Thus, CPPs have potential application as AMPs with dual actions
as both antibiotics and possible molecular transporter properties.
We have synthesized and evaluated several cyclic CPPs as molecular transporters
of other cargo drugs. For example, we recently reported that synthetic cyclic peptides
[WR]4 and [WR]5 enhanced the cellular uptake of phosphopeptides, doxorubicin, and
anti-HIV drugs.15 These peptides are expected to be more stable than linear peptides
towards human serum because the cyclization decreases proteolytic degradation.16 It
has been previously reported that the rigidity in the peptides can enhance the cellpenetrating property.17 According to our recent study, the acylation and cyclization of
short polyarginine peptides enhance the intracellular delivery of cell-impermeable
phosphopeptides.
In general, AMPs contain hydrophobic and hydrophilic portions that interact with
the lipid part and hydrophilic negatively charged heads in bacteria membranes,
respectively. Many linear AMPs adopt amphipathic α-helix conformations with the
hydrophobic side chains arranged along one side of the helical structure and the
hydrophilic side chains organized on the opposite side. This arrangement results in the
ideal amphipathic helical structures.18 Some AMPs form amphipathic -sheet
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conformation to interact with cell membranes.18 We hypothesized that amphiphilic
cyclic peptides with cell-penetrating property can have potential antibacterial and
synergistic activity with other antibiotics. Herein, we report two classes of amphiphilic
cyclic CPPs: (a) cyclic peptides containing tryptophan and arginine amino acids and
(b) fatty acylated cyclic polyarginine peptides (ACPPs). The antimicrobial activities of
synthesized peptides were evaluated against multidrug-resistant bacterial pathogens.

EXPERIMENTAL SECTION
Peptide Design and Synthesis. The peptides were synthesized by Fmoc/tBu solidphase peptide synthesis. Single amino acid (tryptophan or arginine) preloaded trityl
resins were employed for the synthesis of cyclic peptides. Fmoc-L-amino acid
building blocks were coupled to the resin using the 2-(1H−benzotriazole-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HBTU), hydroxybenzotriazole (HOBT),
and N,N-diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF). Fmoc
protecting groups were removed by treatment with 20% (v/v) piperidine in DMF after
each coupling. The side chain protected peptides were detached from the resin by
2,2,2-trifluoroethanol (TFE)/acetic acid/dichloromethane (DCM) (2:1:7, v/v/v), and
cyclized using 1-hydroxy-7-azabenzotriazole (HOAT), N,N-diisopropylcarbodiimide
(DIC) in anhydrous DMF/DCM. Then all protecting groups were removed with
trifluoroacetic acid/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2, v/v/v/v) mixture,
and crude peptides were collected by precipitation with cold diethyl ether. The crude
cyclic peptides were purified by a reversed-phase high pressure liquid chromatography
(RP-HPLC) system using a preparative Phenomenex Gemini C18 column (10 μm, 250
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× 21.2 mm) with a gradient 0-100% of acetonitrile (CH3CN) containing 0.1% TFA
(v/v) and water containing 0.1% TFA (v/v) for 1 h with a flow rate of 15.0 mL/min at
the wavelength of 214 nm.
As a representative example, the synthesis of peptide 1 ([R4W4]) is described
here. After swelling of H-Trp(Boc)-2-chlorotrityl resin (449 mg, 0.35 mmol, 0.78
mmol/g) in DMF for 40 min by N2, three consecutive coupling of Fmoc-Trp(Boc)-OH
(553 mg, 1.05 mmol, 3 equiv) with the resin was carried out using HBTU (398 mg,
1.05 mmol, 3 equiv), HOBT (142 mg, 1.05 mmol, 3 equiv), and DIPEA (366 µL, 2.1
mmol, 6 equiv) in DMF (15 mL). In each coupling step, the mixture of resin and
reaction solution was agitated using N2 for 1 h. Piperidine in DMF (20% v/v) was used
to remove Fmoc group after each coupling. The subsequent Fmoc-Arg(Pbf)-OH (681
mg, 1.05 mmol, 3 equiv) coupling was conducted four times in a similar manner. The
linear peptide with protected side chain was cleaved from the resin in the presence of
TFE/acetic acid/DCM (2:1:7, v/v/v) for 1 h. After evaporation and overnight drying of
the filtrate in a vacuum, the cyclization was carried out under a dilute condition. The
linear peptide was dissolved in anhydrous DMF/DCM (5:3, v/v, 250 mL). HOAT (190
mg, 1.4 mmol, 4 equiv), and DIC (240 μL, 1.54 mmol, 4.4 equiv) were added to the
solution. The reaction mixture was stirred for 12 h under nitrogen atmosphere. Then,
the solvent was evaporated. Reagent ″R″, trifluoroacetic acid/thioanisole/1,2ethanedithiol/anisole (90:5:3:2, v/v/v/v), was added, and the solution was mixed for 2
h to remove side chain protecting groups. The crude peptide 1 was precipitated and
washed with cold diethyl ether, and purified by a preparative RP-HPLC system as
described above.
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The peptide structures were confirmed by an AXIMA performance matrixassisted laser desorption/ionization-time of flight (MALDI-TOF) spectrometer. The
sequence of synthesized fourteen peptides is shown in Table 1. Fluorescein-labeled
peptide 1 (F′-[KR4W4]) was synthesized by conjugation of a cyclic peptide (-Ala)[KR4W4] and 5(6)-carboxyfluorescein N-hydroxysuccinimide ester in solution phase.
A cyclic peptide (-Ala)-[KR4W4] was synthesized using the same protocol described
above but Dde-Lys(Fmoc)-OH was added for attachment of Boc--Ala-OH on the
side chain of lysine.

[RRRRWWWW] (1): MALDI-TOF (m/z): C68H88N24O8 calcd. 1368.7217; found
1369.6412 [M + H]+. RRRRWWWW-COOH (2): MALDI-TOF (m/z): C68H90N24O9
calcd. 1386.7323; found 1387.3780 [M + H]+. [RRRRWWW] (3): MALDI-TOF
(m/z): C57H78N22O7 calcd. 1182.6424; found 1183.5685 [M + H]+. RRRRWWWCOOH (4): MALDI-TOF (m/z): C57H80N22O8 calcd. 1200.6529; found 1201.5652 [M
+ H]+. [EEEEWWWW] (5): MALDI-TOF (m/z): C64H68N12O16 calcd. 1260.4876;
found 1261.3981 [M + H]+, 1283.4336 [M + Na]+, 1299.4365 [M + K]+.
[EEEEWWW] (6): MALDI-TOF (m/z): C53H58N10O15 calcd. 1074.4083; found
1075.4027 [M + H]+, 1113.4099 [M + K]+. [KRRRRR] (7): MALDI-TOF (m/z):
C36H72N22O6 calcd. 908.6005; found 909.6772 [M + H]+. Dodecanoyl-[KRRRRR]
(8): MALDI-TOF (m/z): C44H86N22O7 calcd. 1034.7050; found 1035.7084 [M + H]+.
Dodecanoyl-[KRRRRR] (9): MALDI-TOF (m/z): C48H94N22O7 calcd. 1090.7676;
found 1091.7576 [M + H]+. Hexadecanoyl-[KRRRRR] (10): MALDI-TOF (m/z):
C52H102N22O7 calcd. 1146.8302; found 1147.8404 [M + H]+. N-Acetyl-L89

tryptophanyl-12-aminododecanoyl-[KRRRRR]

(11):

MALDI-TOF

(m/z):

C61H107N25O9 calcd. 1333.8684; found 1334.8713 [M + H]+. N-Acetyl-WWWW[KRRRRR] (12): MALDI-TOF (m/z): C82H114N30O11 calcd. 1694.9283; found
1696.3111 [M + H]+. Dodecanoyl-[KRRRRRR] (13): MALDI-TOF (m/z):
C54H106N26O8 calcd. 1246.8687; found 1247.7397 [M + H]+. Dodecanoyl-KRRRRRCOOH (14): MALDI-TOF (m/z): C48H96N22O8 calcd. 1108.7781; found 1109.7308
[M + H]+.

F′-[KR4W4]. Fluorescein-labeled peptide F′-[KR4W4] was synthesized using the same
protocol, but a lysine residue was added to attach a fluorescein. First, (-Ala)[KR4W4] was synthesized in 0.10 mmol scale. H-Trp(Boc)-2-chlorotrityl resin (128
mg, 0.10 mmol, 0.78 mmol/g), Fmoc-Trp(Boc)-OH (158 mg, 0.30 mmol, 3 equiv),
Fmoc-Arg(Pbf)-OH (195 mg, 0.30 mmol, 3 equiv), Dde-Lys(Fmoc)-OH (160 mg,
0.30 mmol, 3 equiv), and Boc--Ala-OH (57 mg, 0.30 mmol, 3 equiv) were used to
couple each building block to the resin using HBTU (114 mg, 0.30 mmol, 3 equiv),
HOBT (41 mg, 0.30 mmol, 3 equiv), and DIPEA (105 µL, 0.60 mmol, 6 equiv) in
DMF. Dde protecting group was removed with 2% hydrazine in DMF, and side chain
protected linear peptides were cleaved from the resin using TFE/acetic acid/DCM
(2:1:7, v/v/v). The subsequent cyclization and purification steps were the same as
described above.
The (-Ala)-[KR4W4] peptide (8.00 mg, 5.10 µmol) and 5(6)-carboxyfluorescein
N-hydroxysuccinimide ester (FAM-NHS, 3.14 mg, 6.63 µmol, 1.3 equiv) was coupled
using PyAOP (3.46 mg, 6.63 µmol, 1.3 equiv), and DIPEA (8.9 µL, 51.0 µmol, 10
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equiv) in anhydrous DMF (200 µL) and a few drops of anhydrous DCM. The reaction
mixture was stirred for 3.5 h under N2. After evaporation of the solvent, the residue
was purified using a preparative RP-HPLC system using the same condition described
above. After removal of Dde protecting group with 2% hydrazine in DMF and
washing with DMF and DCM, side chain protected fluorescein linear peptides were
cleaved from the resin using TFE/acetic acid/DCM (2:1:7, v/v/v). The subsequent
cyclization and purification steps were described above. F′-[KW4R4]: MALDI-TOF
(m/z): C98H115N27O16 calcd. 1925.9015; found 1926.8654 [M + H]+.

Bacterial Strains. Methicillin-resistant Staphylococcus aureus (MRSA; ATCC
43300), Pseudomonas aeruginosa (PAO1), and Escherichia coli (ATCC 35218) were
employed for antimicrobial activities of peptides alone and in the combination with
tetracycline.

Antibacterial Activities against MRSA and P. aeruginosa. MRSA and P.
aeruginosa were inoculated into tryptic soy broth (TSB, BDTM) at 37 C and shaken at
175 rpm overnight. The cultured suspension (1 × 108 CFU/mL) was immediately
diluted into 1 × 105 CFU/mL. All fourteen peptides were dissolved in distilled water
(except for peptides 5 and 6, dissolved in 50 mM NH4HCO3 solution to increase
solubility) to make 5 mM solutions, respectively. Tetracycline and tobramycin were
used as positive control and prepared as 0.10 mg/mL solution and 0.094 mg/mL.
Minimal inhibitory concentration (MIC) was determined by the two-fold broth
microdilution method according to National Committee for Clinical Laboratory
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Standards (NCCLS) guidelines.19 Briefly, in a 96-well microtiter plate, all tested
peptides and control were mixed well with bacteria suspension (1:39, v/v). After a
series of two-fold dilution, the microtiter plates were then incubated statically at 37 C
overnight. Absorbance was read at 600 nm by plate reader (SpectraMax M2,
Molecular Devices). MIC of each peptide was determined as the minimum
concentration where no visible bacterial growth was present.

Additionally,

combination activity of peptide 1, 7, 9, 10, and 13 were assessed by mixing with
tetracycline and bacteria suspension (1:1:38, v/v/v). MICs were determined as the
same procedures described above. All experiments were triplicated.

Time-Kill Studies. Time-kill studies were performed using MRSA (ATCC 43300)
and E. coli (ATCC 35218). Strains were incubated at 37 °C for 18-24 h on tryptic soy
agar (TSA; Difco, Becton Dickinson Co., Sparks, MD) and a McFarland standard was
diluted in Mueller Hinton Broth (MHB; Becton Dickinson Co., Sparks, MD)
supplemented with 25 mg/L calcium and 12.5 mg/L magnesium, to a final
concentration of ~5.5 log10 CFU/mL.21 Peptide 1 ([R4W4]) and tetracycline were
evaluated at one, two, four, and eight times their respective MICs. Peptide 1 at two
times the MIC was also combined with tetracycline at one, two, four and eight times
the MIC to evaluate for synergy, defined as >2 log10 CFU/mL reduction over the most
active agent alone. Each bacterial-antimicrobial combination was run in triplicate.
Runs in the absence of antimicrobials ensured adequate growth of the organisms in the
model. Each culture was incubated in a shaking incubator (Excella E24, New
Brunswick Scientific, Enfield, CT) at 37°C for an additional 24 h. Samples were taken
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at 0, 4, and 24 h, serially diluted, and plated on TSA for colony count enumeration,
where the limit of detection was 2.0 log10 CFU/mL.21 Bactericidal activity (99.9% kill)
was defined as a ≥3 log10 CFU/mL reduction at 24 h in colony count from the initial
inoculum. Bacteriostatic activity was defined as a <3 log10 CFU/mL reduction.

Cellular Cytotoxicity Assays. MTS proliferation assays were carried out against three
cell lines (human ovarian adenocarcinoma SK-OV-3, human leukemia CCRF-CEM,
and human embryonic kidney HEK 293T). Cells were seeded into 96-well plates (5 ×
103 cells for SK-OV-3, 1 × 105 cells for CCRF-CEM, and 1 × 104 cells for HEK 293T)
and incubated overnight with 100 L of complete media for overnight at 37 C with
5% CO2. Various concentrations (0 – 600 M) of the peptide solution (10 L) were
added to cells. The cells were kept in an incubator (37 C, 5% CO2) for 24 h. Then
CellTiter 96 aqueous solution (20 L) was added into each well and incubated for 1-4
h at the same condition. The absorbance was obtained at 490 nm using a microplate
reader. Wells containing cells in the absence of any peptide were used as control.

Cellular Uptake of Fluorescein-labeled Peptide 1 (F′-[KW4R4]). SK-OV-3 cells
were grown in 6-well plates (2 × 105 cells/well) with complete EMEM media prior 24
h to cellular uptake assay. A 1 mM of fluorescein-labeled peptide stock solution was
prepared in water and diluted in Gibco® Opti-MEM® I reduced serum medium to
prepare a 5 M final concentration. The culture media were removed from 6-well
plates, and the 5 M fluorescein-labeled peptide solution was added. After 1 h
incubation, trypsin-EDTA solution was added to detach cells from plate’s surface and
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remove cell surface binding peptides. After 5 min. treatment with trypsin-EDTA, a
portion of complete media was added to stop the activity of trypsin. The cell lines
were collected and centrifuged at 2500 rpm. Then cells were washed twice using PBS
without calcium and magnesium, and prepared in FACS buffer for cell sorting. The
cells were analyzed by BD FACSVerse™ flow cytometer using FITC channel. The
data collection was based on the mean fluorescence signal for 10,000 cells. All assays
were carried out in triplicate. 5(6)-Carboxyfluorescein (FAM) was used as a negative
control.

Mechanism Study of Cellular Uptake by Removing Energy Sources. To examine
the cellular uptake mechanism F′-[KR4W4] at low temperature, the uptake assay was
carried out at 4 °C to inhibit the energy-dependent cellular uptake. SK-OV-3 cells
were preincubated at 4 °C for 15 min and then incubated with the fluorescein-labeled
peptide for 1 h at 4 °C. Cells were collected and assessed with the same protocol
described in cellular uptake of the fluorescein-labeled peptide. The data collected at 37
°C were used for control. For the ATP-depletion assay, cells were incubated with 10
mM sodium azide and 50 mM 2-deoxy-D-glucose for 1 h before adding the
fluorescein-labeled peptide. During 1 h incubation, the 5 M of F′-[KR4W4] was
prepared in the Opti-MEM® I reduced serum medium in the presence of 10 mM
sodium azide and 50 mM 2-deoxy- D-glucose. Then the cells were incubated with this
solution for 1 h. The subsequent sample preparation and flow cytometry analysis
protocol were similar to the protocol described above.
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Confocal Laser Scanning Microscopy (CLSM). SK-OV-3 cells were seeded with
complete EMEM on coverslips in 6-well plate (1 × 105 cells/well) and kept until 50%
confluency. The media were removed, and cells were incubated with 10 M F′[KR4W4] in Gibco® Opti-MEM® I reduced serum medium (Life Technologies, Grand
Island, NY) for 1 h at 37 C. Then cells were washed with 1× phosphate buffered
saline with calcium and magnesium (PBS+) three times. The coverslips were mounted
on microscope slides, and images were obtained using Carl Zeiss LSM 700 system
with a 488 nm argon ion laser excitation and a BP 505-530 nm band pass filter.

RESULTS AND DISCUSSION
Chemistry
All fourteen peptides 1-14 (Table 1) were synthesized by Fmoc/tBu solid-phase
peptide synthesis as described above. Peptides 1-6 were synthesized for this study and
peptides 7-14 have already been reported in Manuscript II for cellular uptake. Peptides
1-4 were designed to have positive charge and hydrophobic moieties. On the other
hand, peptides 5 and 6 were designed to have negative charge and hydrophobic
moieties for comparative studies. Peptides 7-13 have cyclic polyarginines and
hydrophobic fatty acids or tryptophan. Peptide 14 was synthesized as linear
counterpart of peptide 13. The chemical structures of synthesized peptides are shown
in Figure 1.
As a representative example, the synthesis of [R4W4] is described here (Scheme
1). Fmoc-Trp(Boc)-OH was coupled on H-Trp(Boc)-2-chlorotrityl resin three times
using HBTU, HOBT, and DIPEA in DMF. Piperidine in DMF (20% v/v) was used to
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remove Fmoc group after each coupling. The subsequent coupling of Fmoc-Arg(pbf)OH was conducted four times in a similar manner. The linear peptide with protected
side chain was cleaved from the resin using TFE/acetic acid/DCM (2:1:7, v/v/v) and
cyclized in the presence of HOAT and DIC. Reagent ″R″, trifluoroacetic
acid/thioanisole/1,2-ethanedithiol/anisole (90:5:3:2 v/v/v/v), was added to remove side
chain protecting groups to yield crude peptide 1. The peptide was purified by a
preparative RP-HPLC system as described in the experimental section.

Antibacterial Activities
MIC and IC50 values were measured for the fourteen peptides against MRSA and
P. aeruginosa (Table 2). These two bacterial strains are the representative strains of
Gram-positive and Gram-negative pathogens. MRSA is the most common Grampositive pathogen that causes life-threatening infection, while Pseudomonas
aeruginosa is a Gram-negative multi-drug resistant pathogen which can use multidrug
efflux pumps and gene mutations.22 Overall, these peptides were more potent against
the Gram-positive MRSA than the Gram-negative P. aeruginosa. The lowest MIC
values against P. aeruginosa was 21.7 µg/mL (15.6 µM) of peptide 2 while other
compounds showed MICs more than 37.0 µg/mL (31.3 µM). Peptide 1 was the most
potent peptide against MRSA with a MIC value 2.67 µg/mL (1.95 µM). Cyclic
peptides 1, 3, 9, 10, and 13 showed better antibacterial activities compared to linear
peptides 2, 4, and 14. Acylated cyclic peptides 9, 10, and 13 exhibited more potent
activity than the non-acylated cyclic peptide 7. These data are consistent with the cellpenetrating property of amphiphilic peptides described in Manuscript II. The
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correlation between antimicrobial activity and cell-penetrating property is presumably
due to the interaction between positively charged amphiphilc peptides and bacterial
membranes that have negatively charged components. These data explain why
negatively charged peptides 5 and 6 did not show any antibacterial activities. Peptide 1
showed promising results as an antimicrobial peptide against MRSA. Thus, it was
selected for further synergistic studies.

Combination effect of peptides and tetracycline against MRSA
Based on antibacterial activity screening, peptides 1, 9, 10, and 13 were selected
to determine whether they could increase the antibacterial activity when co-incubated
with tetracycline. Non-acylated cyclic peptide 7 was used as a control since it showed
the lowest potency and was structurally different from other cyclic peptides. Peptide 1
in combination with tetracycline showed the most potent antibacterial activity with a
MIC value of 0.12 µg/mL against MRSA (Table 3). Peptides 9, 10, and 13 exhibited
MIC values of 0.19-0.22 µg/mL. Among all peptides, control non-acylated peptide 7
exhibited the lowest potency (MIC = 0.31 µg/mL).
Fraction inhibitory concentration (FIC) index has been widely used to examine
the interaction between two antibiotics.23 When drug A and drug B are applied in
combination, FIC index can be calculated by the equation ‘FIC index = MIC (A in
combination with B)/MIC (A alone) + MIC (B in combination with A)/ MIC (B
alone)’.24,25 The FIC index values are interpreted as ‘synergy’ with FIC ≤ 0.5, ‘partial
synergy’ with FIC between 0.5 and 1, ‘indifference’ with FIC 1-4, and ‘antagonism’
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with FIC > 4.23,26,27 According to this definition, the combination of peptide 1 and
tetracycline can be defined as partial synergy (Table 3).

Time-kill Studies against MRSA and E. coli
Time-kill studies were conducted to evaluate the antimicrobial activity of peptide
1 alone and in combination with tetracycline against MRSA and E. coli over 24 h.
Peptide 1 and tetracycline alone did not demonstrate bactericidal (>3 log10 CFU/mL
reduction) activity against MRSA. Combinations of two times the MIC of peptide 1
with four and eight times the MIC of tetracycline demonstrated bactericidal activity
against MRSA by 24 h. Thus, combinations of peptide 1 and tetracycline did not meet
the definition for synergy against MRSA. However, the combination of the two
compounds turned the bacteriostatic activities of tetracycline and peptide 1 into the
bactericidal activity.
Peptide 1 alone was able to produce bactericidal activity alone against E. coli
only at the highest concentration tested (8× the MIC). All combinations of peptide 1
and tetracycline demonstrated bactericidal activity at 24 h. The combination of eight
times the MIC of tetracycline and 2× the MIC of peptide 1 also demonstrated synergy
at 24 h. More studies are required to determine the mechanism of synergism. One
assumption is that amphiphilic peptide 1 acts as cell-penetrating peptide and can
deliver tetracycline at higher concentration. The fluorescence studies using peptide 1
and tetracycline were challenging because emission and excitation range for
tetracycline were outside the range determined by the flow cytometer.
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Cytotoxicity Assay of Peptide 1
The cytotoxicity of peptide 1 was evaluated by MTS proliferation assay against
human ovarian adenocarcinoma SK-OV-3, human leukemia CCRF-CEM, and human
embryonic kidney HEK 293T cell lines. In both cancer and normal cell lines, the
compound showed more than 84% cell viability at 15 µM (20.5 µg/mL) concentration
(Figure 3). Peptide 1 alone showed 2.67 µg/mL MIC against MRSA that is
significantly lower than the cytotoxic concentration of peptide 1. Furthermore, the
therapeutic index peptide 1 was increased when was combined with tetracycline
showing a MIC value of 0.12 µg/mL, exhibiting partial synergistic effect. Therefore,
the combination of peptide 1 with tetracycline can be used to enhance the therapeutic
index.

Cell-Penetrating Property of Peptide 1 ([R4W4])
Peptide 1 was originally designed as a CPP to have cell-penetrating property.
Thus, we synthesized fluorescein-labeled peptide 1 (F′-[KR4W4]) for cellular uptake
assays, where F is fluorescein. The fluorescein-labeled peptide, F′-[KR4W4] (10 M)
was added to SK-OV-3 cells and incubated for 1 h at 37 C. Confocal laser scanning
microscope (CLSM) images showed that the fluorescein-labeled peptide was dispersed
into the nucleus and cytosol (Figure 4), but no significant fluorescence was observed
in the cells treated with fluorescein alone under the similar condition (data not shown).
The mechanism of cellular uptake was investigated by a temperature control
assay at 4 °C and ATP depletion assay. The cellular uptake of peptide 1 was decreased
about 59% at 4 °C, indicating that the cellular uptake occurred by both endocytotic
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and nonendocytotic pathways (Figure 5). ATP depletion assay also supports this
mixed pathways because there was 80% intracellular transportation even though all
energy source was blocked by sodium azide and 2-deoxy-D-glucose. These results
were consistent with the previous studies that indicated that intracellular transportation
can be controlled by several mixed pathways.28

CONCLUSION
Amphiphilic cyclic CPPs (peptides 1, 9, 10, and 13) exhibited potent antibacterial
activities against Gram-positive MRSA in the range of 2.67–9.75 µg/mL. Cyclic
peptides showed better antibacterial activities compared to the corresponding linear
counterparts. Fatty acylated cyclic peptides exhibited more potency versus nonacylated cyclic peptide. The antibacterial activity correlates well with cell-penetrating
property of the same peptides. These data suggest that amphiphilic cyclic CPPs with
improved cellular uptake leads to more potent antibacterial activity. Moreover, we
found the combination of amphiphilic cyclic CPPs with tetracycline can be partially
synergistic and thus may be more effective in the treatment of multidrug-resistant
pathogens. Time-kill study showed both peptide 1 and tetracycline had bacteriostatic
activities for MRSA and E. coli. However, the combination of those two compounds
exhibited bactericidal activities in both pathogens. The data provide insights in
exploring the combination of amphiphilic cyclic peptides with other antibiotics. This
study suggests that amphiphilic cyclic CPPs could provide alternative strategy in
defeating life-threatening infectious diseases.
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ABBREVIATIONS
AMPs, antimicrobial peptides; ACPPs, acylated cyclic polyarginine peptides;
ATP, adenosine triphosphate; Boc, tert-Butoxycarbonyl; CCRF-CEM, human
leukemia carcinoma cell line; CFU, colony-forming unit; CLSM, confocal laser
scanning microscopy; CPPs, cell-penetrating peptides; DCM, dichloromethane; Dde,
1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl;
diisopropylcarbodiimide;

DIPEA,

N,N-

DIC,

N,N-diisopropylethylamine;

DMF,

N,N-

dimethylformamide; EDT, 1,2-ethanedithiol; EDTA, ethylenediaminetetraacetic acid;
EMEM, eagle’s minimum essential medium; FAM, 5(6)-carboxyfluorescein; FAMNHS, 5(6)-carboxyfluorescein N-hydroxysuccinimide ester; FBS, fetal bovine serum;
Fmoc, 9-fluorenylmethoxycarbonyl; FACS, fluorescence activated cell sorter; HBTU,
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate;

HEK

293T, human embryonic kidney cell line; HOAT, 1-hydroxy-7-azabenzotriazole; HIV,
human immunodeficiency virus; HOBT,

hydroxybenzotriazole;

MALDI-TOF,

matrix-assisted laser desorption/ionization-time of flight; MHB, Mueller Hinton

101

Broth; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant
Staphylococcus

aureus;

MTS,

(3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium);

Pbf,

2,2,4,6,7-

pentamethyldihydrobenzofuran-5-sulfonyl; PBS, phosphate buffered saline; PyAOP,
7-azabenzotriazol-1-yl-oxytris(pyrrolidino)phosphonium hexafluorophosphate; RPHPLC, reversed-phase high pressure liquid chromatography; SK-OV-3, human
ovarian adenocarcinoma cell line; TFA, trifluoroacetic acid; TFE, 2,2,2trifluoroethanol; TIS, triisoproylsilane; TSB, tryptic soy broth.
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Table legends
Table 1: Synthetized peptides list used for antimicrobial activity
Table 2: Antibacterial activities of synthetic peptides against Gram-positive and
Gram-negative strains
Table 3: Antimicrobial activity of peptides in combination with tetracycline against
MRSA
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Figure legends
Figure 1: Chemical structures of synthetic peptides examined for antimicrobial
activity
Figure 2: Time-kill curves of peptide 1, tetracycline, and combination for MRSA
(ATCC 43300) and E. coli (ATCC 35218) at 37 °C for 24 h. Peptide 1 at two times the
MIC was combined with tetracycline at one, two, four and eight times (MICs of
peptide 1: 4 µg/mL for MRSA and 16 µg/mL for E. coli; tetracycline (TC): 0.5 µg/mL
for MRSA and 2 µg/mL for E. coli).
Figure 3: Cytotoxicity assay of peptide 1 by MTS-PMS assay (24 h incubation)
Figure 4: Confocal laser scanning microscope image of F′-[KR4W4] (10 µM) in SKOV-3 cells (1 h incubation).
Figure 5: Energy-dependent mechanistic study of intracellular uptake for F′-[KW4R4].
Cellular uptake was investigated under 4 C and ATP depletion conditions.

Scheme legends
Scheme 1: The synthesis of peptide 1 ([R4W4])
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Table 1
Peptide
Peptide sequence
No.

Abbreviation

1

[RRRRWWWW]

[R4W4]

2

RRRRWWWW-COOH

R4W4

3

[RRRRWWW]

[R4W3]

4

RRRRWWW-COOH

R4W3

5

[EEEEWWWW]

[E4W4]

6

[EEEEWWW]

[E4W3]

7

[KRRRRR]

[KR5]

8

Octanoyl-[KRRRRR]

C8-[R5]

9

Dodecanoyl-[KRRRRR]

C12-[R5]

10

Hexadecanoyl-[KRRRRR]

C16-[R5]

11

N-Acetyl-L-tryptophanyl-12-aminododecanoyl-[KRRRRR]

W-C12-[R5]

12

N-Acetyl-WWWW-[KRRRRR]

W4-[R5]

13

Dodecanoyl-[KRRRRRR]

C12-[R6]

14

Dodecanoyl-KRRRRR-COOH

C12-(R5)
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Table 2
Peptide
No.

Methicillin-resistant
Staphylococcus aureus
MIC (µg/mL)a

IC50 (µM) ± SDb

MIC (µg/mL)

IC50 (µM) ± SD

1

2.67 (1.95)

NA

42.8 (31.3)

3.1 ± 0.7

2

43.4 (31.3)

16.3 ± 1.7

21.7 (15.6)

9.6 ± 1.2

3

18.5 (15.6)

10.3 ± 1.0

37.0 (31.3)

9.8 ± 2.7

4

150 (125)

82.5 ± 30.9

150 (125)

33.1 ± 3.1

5

>158 (>125)

NA

>158 (>125)

NA

6

>134 (>125)

NA

>134 (>125)

NA

7

>114 (>125)

NA

>114 (>125)

NA

8

129 (125)

81.1 ± 2.9

>129 (>125)

NA

9

8.53 (7.81)

4.4 ± 0.3

136 (125)

41.0 ± 6.2

10

8.97 (7.81)

4.7 ± 1.6

>143 (>125)

NA

11

83.4 (62.5)

26.2 ± 10.0

167 (125)

44.0 ± 3.9

12

53.0 (31.3)

19.5 ± 3.5

>212 (>125)

NA

13

9.75 (7.81)

3.9 ± 0.02

156 (125)

45.3 ± 5.6

14

69.3 (62.5)

27.7 ± 3.0

>139(>125)

NA

0.13 ± 0.01

0.731 (1.56)

NA

Controlc 0.156 (0.352)
a

Pseudomonas aeruginosa

Value in parenthesis presents MIC in micromolar concentration; bData are presented

as means ± standard deviation where applicable; cTetracycline and tobramycin were
used as control for MRSA and P. aeruginosa, respectively.
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Table 3

a

Compounds

MIC (µg/mL)

IC50 (µM) ± SDa

FIC indexb

1 + TCc

0.12

0.08

0.8

7 + TC

0.31

0.11 ± 0.01

NA

9 + TC

0.20

0.10 ± 0.01

1.2

10 + TC

0.22

0.13 ± 0.04

1.3

13 + TC

0.19

0.13 ± 0.02

1.4

TC

0.15

0.15 ± 0.02

-

Data are presented as means ± standard deviation where applicable; bFraction

inhibitory concentration (FIC) index = MIC (A in combination with B)/MIC (A alone)
+ MIC (B in combination with A)/MIC (B alone). Synergy: FIC ≤ 0.5; partial synergy:
0.5 < FIC ≤ 1; indifference: 1 < FIC ≤ 4; antagonism: FIC > 4; cTC stands for
tetracycline.
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Figure 1

112

Figure 2
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Figure 3
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Figure 4
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Figure 5
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Scheme 1
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